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Background: Depression is a debilitating mood disorder, negatively affecting an 
individual’s health and well-being. Despite this, the aetiology of depression 
remains poorly understood. Consistently, depression treatments are far from 
satisfactory due to limited efficacy and adverse side effects often associated with 
them, suggesting a need to improve the current animal models of depression in 
order to understand the basic mechanisms of the disorder. In an attempt to 
elucidate the pathophysiology of depression, a rodent model of depression 
(maternal separation, MS) is used to study the neurobiological mechanisms 
implicated in depression. However, MS alone produces inconsistent findings and 
often additional stressors are used to exaggerate the effects of MS. To create a 
more robust model of MS, MS rats were exposed to chronic constant light (CCL). 
However, contradictory findings have been reported with CCL. Aims: This study 
aimed to explore the effects of additional CCL in an MS model by measuring 
glutamate and potassium-stimulated [3H]DA release  in the nucleus accumbens 
(NAc), testing the effects of CCL on serotonin (5-HT) levels  in the hypothalamus 
and prefrontal cortex (PFC) and measuring µ-opioid receptor (MOR-1) levels in the 
NAc and orexin receptor (OXR-1 and OXR-2) levels in the  PFC. Methods: In 
order to achieve these aims four experimental groups were chosen, out of which 
two groups; non-maternally separated (NMS) rats and maternally separated (MS) 
rats  were exposed to CCL for 3 weeks during adolescence and the remaining two 
groups; NMS and MS rats were not subjected to CCL. At postnatal day 80 
(adulthood), rats were decapitated and brain tissue collected for analysis of 
glutamate- and potassium-stimulated [3H]DA release in the NAc using in vitro 
superfusion. Serotonin levels in the hypothalamus and PFC were determined 
using Enzyme-Linked ImmunoSorbent Assay (ELISA). Western blot analysis was 
used to measure MOR-1 levels in the NAc, OXR-1 and OXR-2 in the PFC. 
Results: MS caused a significant decrease in glutamate-stimulated [3H]DA 
release in the NAc.  In the NAc shell, CCL exposure revealed a trend towards a 
decrease in [3H]DA release in response to both glutamate- and potassium-
stimulation. Moreover, in the hypothalamus NMS and MS rats subjected to CCL 




CCL exposure. In the PFC CCL had a significant effect on 5-HT levels and it was 
revealed that NMS CCL rats had decreased 5-HT levels compared to NMS rats. 
Similarly, MS CCL rats had significantly decreased 5-HT levels compared to NMS.  
MS and CCL did not have any significant effect on MOR-1 protein levels in the 
NAc. On the other hand, MS rats had increased OXR-1 and OXR-2 proteins levels 
in the PFC compared to NMS and MS CCL rats. Conclusion: MS decreased 
glutamate-stimulated [3H]DA release in the NAc. Serotonin levels in the 
hypothalamus and PFC were altered by the effects of MS and CCL. Furthermore, 
MS exposure increased OXR-1 and OXR-2 protein levels in the PFC. However, 
MS and CCL did not alter MOR-1 protein levels in the NAc. Therefore, this study 
has demonstrated that CCL exaggerated the effects of MS and created a more 













CHAPTER 1: INTRODUCTION 
1.1 Definition and characteristics of major depressive disorder 
(MDD) 
Major depressive disorder (MDD) is characterised by a prolonged depressed 
mood or anhedonia (a loss of interest and pleasure in partaking in daily activities 
such as occupational and educational activities) which often persists for a 
minimum of 2 weeks (American Psychiatric Association, 2013). During this period, 
depressed individuals often experience additional symptoms such as changes in 
appetite, weight and sleep patterns, further interfering with the individual’s life style 
and well-being (American Psychiatric Association, 2013). Moreover, fatigue, loss 
of energy, poor concentration, indecisiveness, suicidal thoughts, feelings of 
worthlessness and guilt are also reported in depressed individuals (American 
Psychiatric Association, 2013). Depression affects both women and men; however 
women are more prone to developing depression than men (Rubinow et al., 1998; 
Cochran and Rabinowitz, 2000; American Psychiatric Association, 2013). 
1.2 Prevalence of depression  
Depression is one of the most prevalent psychiatric disorders affecting 
approximately 10- 15% of the population at some point in their lives (World Health 
Organisation, 1996). It is considered to be more detrimental to health than chronic 
diseases like diabetes and arthritis, which is indicative of the burden this disorder 
has on health (Moussavi et al., 2007). Furthermore, depression is proposed to be 
the fourth major cause of disability globally and is believed to be the highest cause 
of disease burden in the next decade, further providing evidence of the debilitating 
effects of depression on health (Murray and Lopez, 1997; World Health 
Organisation, 2010). It is also estimated that about 9 million people are diagnosed 
annually with depression in the USA alone (Kessler et al., 2005). These high levels 
of depression have profound cost implications due to lost productivity as well as 




billion and £9 billion are spent in the USA and UK respectively on treating 
depression (Kessler et al., 2005; Kessler, 2012). Although, the pravalance of 
depression is low in South Africa (9.7 %) compared to the USA (21.4 %), cases of 
lost productivity have also been documented, indicating the severity of depression 
on health (Tomlinson et al., 2009). 
Despite the detrimental effects of depression on economy, health and lifestyle, the 
aetiology and pathology of depression is still not fully understood as depression is 
a result of complex interactions involving genetic, epigenetic, biochemical, 
environmental and psychosocial factors (Billings et al., 1983; Brown and 
Anderson, 1991; Judd et al., 1996; Lupien et al., 2009). However, attempts have 
been made to treat depressed individuals using several treatment strategies which 
include antidepressant drugs, psychotherapy, electroconvulsive therapy (ECT), 
brain stimulating therapies and light therapy (Rosenthal et al., 1984; Kripke et al., 
1992; Rohan et al., 2004; Lisanby et al., 2007; Ashkenazy et al., 2009). 
1.3 Treatment of depression  
Earlier studies considered depression to be caused by deficient monoamine levels 
such as serotonin (5-HT), norepinephrine (NE) or even dopamine (DA) at specific 
receptor sites (Schildkraut, 1965). When this hypothesis was introduced it led to 
an important fundamental principle in understanding the neuro-pathophysiology of 
depression (Mao, 2011; Willner et al., 2013).  However, this hypothesis has been 
further refined since the 1960s as more evidence has been accumulated over the 
years. Further research suggests that other biological systems (e.g. abnormal 
circadian rhythms) other than the monoamine systems are also implicated in the 
pathophysiology of depression (Jindal and Thase, 2004;  Fuchs et al., 2006; 
Marazzotti et al., 2009; Willner et al., 2013). Despite this, the monoamine 
depression hypothesis remains a central research area aiding in the development 
of new medication for treating depression (Willner et al., 2013).  
Antidepressant drugs are one of the most widely used treatments for depression 




levels of 5-HT, NE and DA and, increase their neurotransmission at receptor sites 
by blocking their reuptake into presynaptic terminals (Khwawam et al., 2006; 
Denese and Pariente, 2008; Willner et al., 2013). Initial medication included 
tricyclic compounds such as imipramine and monoamine oxidase inhibitors, 
iproniazids which also reverse depressive symptoms by increasing 5-HT, NE and 
DA levels through inhibition of their re-uptake transporters and enzymes that break 
down 5-HT, NE and DA monoamines (Khwawam et al., 2006; Denese and 
Pariente, 2008; Willner et al., 2013). Despite the high efficacy of these drugs in 
treating depression, they are no longer popular as they induce unwanted side 
effects such as heart problems, dizziness, drowsiness, dry mouth and weight gain 
(Nestler, 1998; Khwawam et al., 2006; Denese and Pariente, 2008). As a result, 
newer antidepressants are commonly used since they are better tolerated and 
have fewer side effects than older antidepressants (Monteleone et al., 1995; Papp 
et al., 2003; Khwawam et al., 2006; Kennedy et al., 2006; Sanz and Arranz, 2008).  
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline and 
escitalopram are the most commonly used antidepressants. Serotonin and 
norepinephrine reuptake inhibitors (SNRIs) consisting of venlafaxine, sibutramine 
and duloxetine, are similar to SSRIs and also form part of newer generation 
antidepressants (Khawam et al., 2006; Denese and Pariente, 2008; Lanfumey et 
al., 2013).  SSRIs selectivity inhibit the reuptake of only 5-HT whereas the SNRIs 
inhibits both 5-HT and NE reuptake transporters thereby leading to increased 5-HT 
and NE levels in the synaptic cleft. Antidepressants used to enhance DA 
neurotransmission (e.g. bupropion) are also effective in relieving depressive 
symptomology (Chouinard, 1983; Ferris and Cooper, 1993).  
SSRIs and SNRIs have also been reported to produce headaches, nausea, 
insomnia, and sexual problems and even increase the risk of seizures, suggesting 
that they are far from satisfactory due to these adverse side effects (Khwawam et 
al., 2006; Ginsberg, 2009; Fava and Ffidan, 2011). Despite the replacement of 
older antidepressants by newer ones, antidepressants continue to have delayed 
onset of action and variable response rates (Khwawam et al., 2006; Ginsberg, 
2009; Holtzheimer and Mayberg, 2011). For example, a large percentage of 




large percentage tend to relapse even if the medication is continued for 6 months 
to a year following behavioural recovery (Trivedi et al., 2006; Sartorius et al., 2007; 
Holtzheimer and Mayberg, 2011).  
Depressed individuals are also provided with strategies and solutions to assist in 
coping with stress and negative thoughts in an attempt to manage the disorder 
and to allow them to resume their daily activities (American Psychiatric 
Association, 2000). This form of treatment is called psychotherapy and is made up 
of two types of therapies, namely cognitive behavioural therapy (CBT) and 
interpersonal therapy (IPT) (Reynolds et al., 1999; American Psychiatric 
Association, 2000; Rohan et al., 2004). CBT assists individuals by reconstructing 
their negative thoughts so that they can identify the problems that are causing 
depression thereby preventing the disorder from progressing (American 
Psychiatric Association, 2000).  Similarly, IPT also helps depressed individuals to 
deal with their troubled relationships by finding solutions to manage depression 
and preventing it from progressing (Reynolds et al., 1999; American Psychiatric 
Association, 2000). Psychotherapy can also be used in combination with 
antidepressants in cases where depression is severe (American Psychiatric 
Association, 2000). 
Brain stimulating therapies are used in cases where patients are resistant to 
pharmacological and behavioural treatments (American Psychiatric Association, 
2000; Rohan et al., 2004; Linsanby, 2007). Examples include ECT, vagus nerve 
stimulation and repetitive transcranial magnetic stimulation (Rohan et al., 2004; 
Linsanby, 2007). Brain stimulating therapies involve the application of electrical 
impulses, magnets or implants on the head in order to amplify neurotransmission 
at synapses, especially in brain areas implicated in depression (American 
Psychiatric Association, 2000; Rohan et al., 2004; Linsanby, 2007). For example, 
ECT is the oldest and most widely used stimulation therapy. This technique is 
performed by placing electrodes on certain areas of the head that enable electrical 
current to flow through the brain (APA American Psychiatric Association, 2000, 
Rohan et al., 2004; Linsanby, 2007). ECT is usually administered 3 times in a 




Sleep deprivation and light therapy are gaining more attention in the medical 
research field, not only as a treatment for depression but also as a model to study 
the pathophysiology of depression (Rosenthal et al., 1984; Kripke et al., 1992; 
Rohan et al., 2004; Gorgulu and Caliyurt, 2009; Dimatelis et al., 2012; Hines et al., 
2013). Sleep deprivation has been shown to have a high success rate 
(approximately 60%) in relieving symptoms of depression; however this effect is 
temporary, lasting for few hours or a month if patients are also treated with 
antidepressant drugs (Wu and Bunney, 1990; Gorgulu and Caliyurt, 2009). 
Furthermore, sleep deprivation has been positively correlated with increased 
serum brain-derived neurotropic factor (BDNF), which is often decreased in 
depressed patients (Haung and Reichardt, 2001; Feng et al., 2003; Karege et al., 
2005; Gorgulu and Caliyurt, 2009). Similarly, 12 hours of sleep deprivation 
improved depressive-like symptoms in C57BI6 mice strain, known to exhibit high 
depressive-like behaviours (Hines et al., 2013).  
One of the earliest studies to explore the effects of light therapy on depression 
was conducted by Rosenthal et al. (1984). Subsequently, other studies have also 
used light therapy to treat depression associated with seasonal affective disorder 
(SAD) (Ashkenazy et al., 2009; Rosenthal et al., 1984; Kripke et al., 1992; Rohan 
et al., 2004). SAD is believed to be caused by disrupted circadian rhythms due to 
shorter light and longer dark periods during autumn and winter seasons 
(Ashkenazy et al., 2009; Rosenthal et al., 1984; Kripke et al., 1992; Rohan et al., 
2004).  As a result, the main function of light therapy is to restore the body’s 
normal circadian rhythms and biological systems such as the opioid receptor 
system, in particular the µ-opioid receptor (MOR) (Kripke et al., 1992; Rohan et al., 
2004; Ashkenazy et al., 2009; Dimatelis et al., 2012).  For example, Dimatelis et 
al. (2012) showed that reduced MOR levels in a rodent model of depression, 
maternal separation (MS), can be reversed by treatment with continuous lighting.   
Despite the improvements in treatments of depression and knowledge about the 
underlying mechanisms of depression, the aetiology of depression is still not fully 
understood. This suggests that new studies are required to elucidate the 
pathophysiology of depression in order to provide more effective treatment.   




depression are crucial for providing further insight into the pathophysiology of 
depression. 
1.4 Early life stressors are risk factors of depression 
Epidemiological studies indicate that depression is caused by many internal and 
external factors that include genetic, environmental and psychosocial factors 
(Billings et al., 1983; Brown et al., 1986; Kendler et al., 1995; Judd et al., 1996; 
Barr et al., 2008). For example, an individual exposed to internal factors such as 
genetic variants associated with depression is at increased risk of developing 
depression, more especially if the same individual is subjected to external factors 
such as early life stress (e.g. childhood abuse) (Figure 1.1). Exposure to early life 
stress during the postnatal period when the brain is still developing might alter the 
stress system, the hypothalamic-pituitary-adrenal (HPA) axis; thereby increasing 
the risk of developing depression later in life (Lupien et al., 2000; Geoffroy et al., 
2006; Albers et al., 2008; Lupien et al., 2009). Therefore, exposure to both internal 
and external factors including a dysregulated HPA axis activity further increases 
the risk of triggering a depressive episode, more especially if the same individual 
is subjected to additional stressors during adulthood (Albers et al., 2008; Lupien et 
al., 2009) (Figure 1.1).  
It is proposed that psychosocial factors, in particular early stressful life events are 
one of the most effective factors to induce depressive episodes (Kendler et al., 
1999). Early adverse life stressors or traumatic experiences do not only 
predispose individuals to depression but also to a number of neuropsychiatric 
disorders (Robertson and Bowlby, 1952; Kendler et al., 2005; Heim et al., 2000, 
2020). Moreover, children subjected to physical, emotional or sexual abuse are 
highly susceptible to mood disorders such as anxiety and depression in adulthood 
(Gibb et al., 2007; Felitti et al., 1998). It is believed that the development of 
depression is caused by a dysregulated HPA axis activity due to early life stress 

















Figure 1.1: Risk factors of depression. A schematic diagram showing the multifactorial relationship between internal (genetic variants) and 
external factors (early life stress e.g. childhood abuse) in the development of depression.  Altered hypothalamic-pituitary-adrenal (HPA) axis 
activity as a result of internal and external factors further increases the risk of developing depression, especially if the individual is subjected to 
additional stressors such as a loss of a job during adulthood.  This might trigger a depressive episode leading to depression (Billigns et al., 




1.5 The stress system: HPA axis 
The HPA axis is considered an important system in mediating stress responses 
(Lupien et al., 2009). During stress, the corticotropin-releasing factor (CRF) 
hormone of the hypothalamus paraventricular nucleus (PVN) binds to the 
receptors of the anterior pituitary gland to stimulate the release of 
adrenocorticotropic hormone (ACTH) (Figure 1.2) (Lupien et al., 2009).  ACTH in 
turn activates the secretion of glucocorticoids (cortisol in humans and 
corticosterone (CORT) in rodents) from the adrenal cortex into the bloodstream 
(Lupien et al., 2009). In order to inhibit further secretion of CORT, the rising 
circulating cortisol exerts a negative feedback inhibition to prevent further release 
of CORT once the stress has passed (Lupien et al., 2009). Negative feedback 
inhibition is mediated through two types of receptors, namely mineralocorticoid 
(MR) and glucocorticoid receptor (GR) (Dallman et al., 1987; de Kloet et al., 1997; 
Lupien et al., 2009). These receptors are expressed in many parts of the central 
nervous system (CNS), in particular in brain areas implicated in the stress 
response such as the hippocampus, amygdala and PFC. These areas are 
important for mediating negative feedback by glucocorticoids on the HPA axis in 
response to stress (de Kloet et al., 1997). The ability of MR and GR receptors to 
suppress the HPA axis activity in response to stress plays an important role in 
enabling an individual to cope or adapt to stress (de Kloet et al., 1997).  
 It is important to note that the severity, chronicity, predictability, coping ability and 
previous exposure to stressors are also factors that influence the way in which 
individuals respond to stressors (Paykel, 2001; Kendler et al., 1999). It is the 
inappropriate response to stress that often leads to increased susceptibility and 
development of psychiatric disorders, including mood disorders (Figure 1.2) 
(Holsboer et al., 1986; Menteleone et al., 1995; de Kloet et al., 1997; Lupien et al., 
2009). The effects of early life stress are often demonstrated by increased HPA 
axis activity, which is considered a hallmark characteristic of depression (Nemeroff 

























Figure 1.2: The stress system, HPA axis.  During a stressful event the HPA axis 
responds by secreting corticotropin releasing hormone (CRH) and arginine vasopressin 
(AVP) from the hypothalamus. The CRH and AVP activate the anterior pituitary gland 
thereby releasing adrenocorticotropic hormone (ACTH) which in turn causes production of 
glucocorticoids such as cortisol and corticosterone (CORT). Increased CORT levels cause 
negative feedback to inhibit further CORT release by activating glucocorticoid receptors 
(mineralocorticoid (MR) and glucocorticoid receptor (GR) which are located in the pituitary 
gland, hypothalamus, hippocampus and frontal cortex. This in turn suppresses HPA axis 
activity leading to decreased production of glucocorticoids thereby maintaining 
homeostasis.  The amygdala is also involved in the regulation of the stress response by 





Increased HPA axis activity is indicated by higher basal plasma cortisol, ACTH 
levels and hyper secretion of CRF, suggesting inability to cope with stress (Pfeffer 
et al., 2007; Holsboer et al., 1986; Menteleone et al., 1995). Prolonged exposure 
to high levels of glucocorticoids impairs the negative feedback mechanism 
responsible for decreasing the HPA axis activity (Pfeffer et al., 2007; Holsboer et 
al., 1986; Menteleone et al., 1995). For example, women who were abused as 
children displayed increased HPA axis activity in response to a standard 
laboratory stressor when matched to non-abused women (Heim et al., 2000). 
Moreover, those with a history of childhood abuse and a recent major depressive 
episode were reported to have more than six fold greater ACTH response to a 
stress compared to controls (Heim et al., 2000).   
The relationship between a parent and a child as well as the psychological state of 
the mother has a potent effect on the activity of the HPA axis of the child (Lupien 
et al., 2009). For example, children whose mothers experienced stress, 
depression and anxiety during pregnancy were reported to have increased basal 
HPA axis activity at 6 months, 5 years and 10 years of age (Lyons-Ruth et al., 
2000; O’Connor et al., 2005). Similarly, children whose mothers were depressed 
during their early life were susceptible to developing enhanced HPA axis activity 
and depression during adolescence (Lupien et al., 2000). Furthermore, children 
that spent a significant amount of time away from their mothers as toddlers in day 
care centres were reported to have altered glucocorticoid levels (Geoffroy et al., 
2006). This means that exposure to stress resulting from child-mother interaction 
can alter the HPA axis activity and increase the risk of experiencing stress or 
mood disorders in later life (Heim et al., 2000; Albers et al., 2008; Lupien et al., 
2009).  
Based on these findings it is evident that early life stressors play a significant role 
in the development of mood disorders, in particular depression. It is important to 
note that childhood represents a critical point in time in which the effects of stress 
exposure can predispose children to developing depression later in life (Albers et 
al., 2008; Lupien et al., 2009). This is because brain areas such as the amygdala, 
hippocampus and frontal cortex which are involved in the regulation of the HPA 




of stress during this stage of development (Figure 1.3) (Lupien et al., 2000; 
Geoffroy et al., 2006; Albers et al., 2008; Lupien et al., 2009).     
 
Figure 1.3: The life cycle model of stress. The impact of stress exposure at different 
stages of life during the development and declining stages of the human brain areas 
(amygdala, frontal cortex and hippocampus) involved in the regulation of the HPA axis 
activity. From birth to 2 years, the hippocampus matures first (represented by the navy 
colour segment of the bar line), followed by the frontal cortex which is fully developed by 
adolescence. Amygdala is the last brain area to mature; its volume only matures in 
adulthood specifically in the late 20s. Despite this, the amygdala is less vulnerable to the 
effects of stress than the frontal cortex since at 2 years of age this area is more developed 
than the frontal cortex which only starts to mature around 8 years of age.  In adulthood 
and aging (orange and red bars represent the brain areas undergoing the most rapid 
decline as a result of aging).  The hippocampus is the first brain area to undergo a rapid 
decline as a result it is most vulnerable to the effects of stress, followed by the frontal 
cortex and amygdala (Lupien et al., 2009). 
Depression continues to affect millions of people around the world and the fact 
that this disease is a major burden on the economy, health and lifestyle makes it a 
serious health concern that needs to be addressed (Murray and Lopez, 1997; 
World Health Organisation, 2010; Kessler, 2012). Hence, it is important to 
understand the underlying mechanisms of depression.  Therefore, it is reasonable 




MS as an ideal model to elucidate the biological mechanisms implicated in 
depression. Not only are animal models useful in elucidating the basic 
mechanisms of the disorder, they are also important in the development of novel 
and more effective therapeutic targets for treating depression (Geyer and Markou, 
1995; Kendler et al., 1999;  Marais et al., 2008; Abelaira et al., 2013).  
1.6 MS as a model of early life stress  
An animal model must adhere to specific criteria in order to model certain aspects 
of the human condition; these criteria include face, construct and predictive validity 
(Table 1.1) (Geyer and Markou, 1995; Abelaira et al., 2013). Face validity refers to 
the similarities between the behaviours exhibited by the animal model and those 
often observed in the human condition (Geyer and Markou, 1995; Abelaira et al., 
2013). Construct validity requires the pathology or neurochemical processes 
displayed in the animal model to be similar to that of a human condition (Geyer 
and Markou, 1995; Abelaira et al., 2013). Predictive validity requires behavioural 
changes in the animal model after treatment to predict similar changes in the 
human condition (Geyer and Markou, 1995; Abelaira et al., 2013). Since early life 
stressors or traumatic experiences during childhood are considered the most 
potent factors to induce neuropsychiatric disorders in particular depression and 
anxiety disorders later in life (Kendler et al., 1999; Paykel 2001; Pryce et al., 2005; 
Geoffroy et al., 2006; Albers et al., 2008; Heim et al., 2010 Abelaira et al., 2013), 
this study has chosen MS as an animal model to study the effects of early adverse 
experiences on the brain. The aim of this study was to increase our understanding 
of the pathophysiology of depression. The use of MS as a model of early life stress 
is further supported by the findings that children subjected to early life stress 




Table 1.1:  Criteria of an animal model for a human disorder 
 
 
Adapted from (Geyer and Markou, 1995; Abelaira et al., 2013)    
Abbreviation: Adrenocorticotropic hormone (ACTH), corticosterone (CORT), forced swim test (FST), hypothalamus-pituitary-adrenal (HPA) 
axis 
Criteria Description Example 
 Face validity Similarities between behaviour exhibited by the animal model and the 
specific symptoms of the human disorder 
Increased immobility time in the FST or decreased 
sucrose intake (anhedonia) in animals should 
correspond to depressive symptoms in humans 
(Ladd et al., 2000; Daniels et al., 2004; Dimatelis 
et al., 2012). 
Construct validity Similarities in the pathophysiology or neurochemical processes of the 
disorder between the animal model and the human disorder 
Dysregulated HPA axis, increased ACTH or CORT 
levels should be observed in both depressed 
animal and human subjects (Aisa et al., 2007; 
Marais et al., 2008). 
Predictive validity States that one should be able to predict changes in the human condition 
based upon the changes in the animal model.  That is, improvement or 
reduction of depressive symptoms observed after treatment in an animal 
should also be observed in a human condition. 
Administration of an antidepressant drug in the 
animal should ameliorate depressive-like 





1.7 Maternal separation (MS) 
MS and early life deprivation are the two most used animal models to study the 
effects of postnatal stress (Aisa et al., 2007; Marais et al., 2008; Zimmerberg et al., 
2009; Dimatelis et al., 2012). Both of these paradigms refer to the separation of 
pups from their mothers (dam) for a short period of time. In an MS model, the pups 
are kept together as a litter as opposed to the early life deprivation model in which 
pups are isolated from the dam and from the rest of the litter (McCormick et al., 
1998; Zimmerberg et al., 2009). One of the earliest studies to investigate the 
effects of MS on behaviour was conducted on infant monkeys (Hinde et al., 1966; 
Hrdina et al., 1979). In this study, separation of the infant monkeys from their 
mothers resulted in behaviour resembling despair in humans (Hinde et al., 1966; 
Hrdina et al., 1979). 
Similarly in rats, separation of pups during the first 3 weeks of life is stressful since 
the pups are completely dependent on their mothers during this period (Slotten et 
al., 2006; Aisa et al., 2007; Marais et al., 2008). MS can be performed for a short 
period (1 hour) or for prolonged periods (3-6 hours) during the 1-3 weeks after 
birth (Hout et al., 2002; Marais et al., 2008; Wilber and Wellmar, 2009). This model 
causes increased basal CORT levels, increased CRF and lower adrenal weight in 
separated rats compared to non-separated rats, indicating that HPA axis activity 
had been altered (Slotten et al., 2006; Aisa et al., 2007; Marais et al., 2008).   
Changes in HPA axis activity of MS animals are associated with anxiety-like 
behaviours in the elevated plus maze (EPM) and open field test (OFT) and 
depressive-like behaviours in the FST (Ladd et al., 2000; Daniels et al., 2004; EL 
Khoury et al., 2006; Marais et al., 2008). Similarly, rats exposed to 3 hours daily of 
MS over 3 weeks from postnatal day (PND); PND2 - 21 spent less time in the 
open arm of the EPM, indicating that animals subjected to MS stress display 
anxiety-like behaviours (Aisa et al., 2007). Similarly, 2 weeks of MS (P2-P14) 
induced anxiety-like behaviours in the EPM (Hout et al., 2001; Lee et al., 2007).  
MS rats also have decreased preference for sucrose solution, which is indicative 




2001). Typically, rats prefer sweetened fluids (sucrose) over water; however this 
preference is reduced after MS (Aisa et al., 2007). 
Due to the altered HPA axis activity, MS rats are further predisposed to reacting to 
additional stressors such as behavioural tests (FST, OFT, EPM) and restraint 
stress that potentiate the effects of MS causing depressive- and anxiety-like 
behaviours in adulthood (Plotsky and Meaney, 1993; Veenema et al., 2006; Lee et 
al., 2007; Marais et al., 2008). Similarly, early life stress when combined with 
subsequent adult stress has been reported to increase the risk of mood disorders, 
specifically depression and anxiety disorders in human studies (Heim et al., 2000; 
Heim et al., 2008). These studies suggest that exposure to additional stressors in 
animals already subjected to MS stress might be useful in providing further insight 
into the aetiology of depression. 
1.8 Chronic constant light (CCL) as an additional stressor 
Over the years it has become evident that depression is not only due to deficient 
monoamine levels as had previously been proposed by Schildkraut (1965). Other 
biological systems such as the circadian rhythms are also implicated in the 
pathophysiology of depression (Jindal and Thase, 2004; Fuchs et al., 2006; 
Willner et al., 2013). Moreover, the fact that sleep disturbance (insomnia or 
hypersomnia), is one of the most prominent features of depression leading to a 
loss of concentration and decreased energy levels, suggests that abnormal 
circadian rhythms may be implicated in the pathophysiology of depression 
(Salomon et al., 2003; Cao and Guilleminault, 2011).   
Circadian rhythms are defined as biological processes that have endogenous 
oscillations with a period of approximately 24 hours (Bailey and Silver, 2014). 
Under normal conditions, the circadian rhythms are synchronised by external 
stimuli called zeitgebers, also known as time givers (Krishnan and Neslter, 2011; 
Bailey and Silver, 2014). The 24 hour light/dark (L/D) cycle is the main entraining 
zeitgeber in the CNS, in particular for the suprachiasmatic nucleus (SCN) of the 




et al., 2012; Bailey and Silver, 2014). The SCN is synchronised by light via 
signalling through the retino hypothalamic tract, one of the three pathways that 
send information to the SCN (Dubocovich, 2007; Krishnan and Neslter, 2011; 
Catena-Dell’Osso et al., 2012; Bailey and Silver, 2014) (Figure 1.4). The other two 
pathways that also send input to the SCN include the geniculo hypothalamic tract 
and the serotonergic (5HT-ergic) systems (including both the dorsal raphe, (DRN) 
and medial raphe nuclei, (MRN) (Dubocovich, 2007; Catena-Dell’Osso et al., 
2012; Krishnan and Neslter, 2011; Bailey and Silver, 2014). The retino 
hypothalamic tract sends photic information from the non-image forming 
photoreceptors known as photosensitive retinal ganglion cells (Provencio et al., 
2000; Berson net al., 2002; Shirani and St Louis, 2009) (Figure 1.8.1). These cells 
contain a photo sensitive pigment, melanopsin, which is important in transmitting 
light synchronising information into neural impulses to be used by the SCN 
(Berson et al., 2002; Moore and Speh, 2004). Similarly, the geniculo hypothalamic 
tract pathway via the intergeniculate leaflet (which in turn receives input from the 
orexin system) also sends photic input to the SCN about the L/D cycle and level of 
arousal (Mintz et al., 2001). The 5HT-ergic neurons that originate from the MRN 
and DRN inhibit SCN activity in response to light (Berson et al., 2002; Moore and 
Speh, 2004) (Figure 1.4).  
The main function of the SCN is to generate circadian rhythms and prepare the 
individual to adapt to the daily changes in the environment (Wirz-Justice, 2006). 
Some of the many biological functions that exhibit circadian rhythms include body 
temperature, heart rate, melatonin, cortisol and growth hormone secretion (Ritcher 
et al., 2004; Mazzolli et al., 2011). The SCN is also known to regulate the circadian 
rhythm of glucocorticoid levels; as a result lesions of the SCN disrupt the secretion 
of CORT (Campbell and Dawson, 1990; Redlin, 2001). In both nocturnal (rodents) 
and diurnal species (humans) an increase in glucocorticoid levels is associated 
with arousal. In diurnal species glucocorticoid levels peak in the early hours of the 
morning, while the opposite is found in nocturnal species (Campbell and Dawson, 
1990; Redlin, 2001). These findings indicate that the SCN plays an important role 






Figure 1.4: Generation of circadian rhythms for biological functions. The 24 hour 
light/dark (L/D) cycle synchronises the suprachiasmatic nuclei (SCN) via the retino 
hypothalamic tract (RHT).  The SCN also receives input from the 5HT-ergic neurons that 
originate from the dorsal and median raphe (DRN and MRN) and from the geniculo 
hypothalamic tract (GHT) which also receives photic and arousal input via the 
intergeniculate leaflet (IGL). Inputs to the SCN lead to the generation of circadian rhythms 
of many important biological functions such as melatonin secretion, locomotor activity and 
glucocorticoid release. Disturbances in this system predispose individuals to developing 
depression (Campbell and Dawson, 1990; Redlin, 2001; Krishnan and Neslter, 2011). 
The AVP neurons of the SCN regulate CRH neurons of the PVN by inhibiting their 
activity during stress (Kalsbeek et al., 1992). However, increased cortisol levels 
decrease AVP activity resulting in failure to inhibit CRH neurons (Liu et al., 2006; 
Kalsbeek et al., 1992).  This in turn causes the CRH neurons to activate the 
anterior pituitary to release ACTH and subsequently releasing more cortisol 
(Kalsbeek et al., 1992). This might explain the decreased SCN activity due to 
increased plasma cortisol levels; suggesting that the interaction of the CRH-AVP 
neurons is crucial for controlling glucocorticoid release in response to stress 
(Kalsbeek et al., 1992; Liu et al., 2006). Therefore, MS exposure might decrease 
SCN activity and predispose rats to additional stress (CCL) in adulthood. CCL 
exposure might also exacerbate the effects of MS by further reducing SCN activity, 




Since melatonin secretion is regulated by both the L/D cycle and exposure to 
stress, processes that control SCN activity, suggests that melatonin production 
might be susceptible to the effects of MS and CCL (Rieter et al., 2000). 
Functionally, melatonin translates photoperiodic information by activating 
melatonin receptors (MT1 and MT2) located in the SCN to regulate many 
physiological functions that vary with season including reproduction, appetite and 
sleep (Rieter et al., 2000; Hazlerigg and Wagner, 2006). MT1 inhibits firing of 
neurons in the SCN and is believed to be involved in promoting sleep (Rieter et al., 
2000). On the other hand, MT2 is responsible for the entrainment of circadian 
rhythms (Hatter et al., 2003). During the dark, the SCN transmits photic input to 
the pineal gland to stimulate pinealocytes to synthesize and release melatonin 
(Campbell and Dawson 1990; Redlin, 2001; Simonneaux & Ribelayga, 2003; 
Catena-Dell ‘Osso et al., 2012). Therefore, darkness activates melatonin synthesis 
whereas light inhibits melatonin production (Monteleone et al., 2011). Melatonin 
secretion is greater at night in both diurnal and nocturnal species (Campbell and 
Dawson, 1990; Redlin, 2001; Claustrat et al., 2005). However, in diurnal species 
melatonin corresponds with decreased activity (beginning of sleep in humans) and 
in nocturnal species melatonin production is associated with increased activity 
(active period in rats) (Nagtegaal et al., 1998). 
Impaired melatonin activity, whereby melatonin secretion is delayed in depressed 
patients compared to controls has been reported by Crasson et al. (2004). 
Furthermore, unipolar and bipolar depressed patients display low levels of 
melatonin (Beck-Frils et al., 1985; Soutre et al., 1989).  The role of melatonin in 
depression is further supported by the findings that melatonin treatment improves 
total sleep time and decreases depressive symptoms (Kayumov et al., 2001). 
These observations indicate that the melatonergic system is necessary for 
maintaining mood. In accordance with this statement, antidepressant-like effects of 
melatonin have been reported and adverse effects of chronic stress are reversed 
by melatonin administration (Kopp et al., 1999). Similarly, agomelatine (an 
analogue of melatonin) is used for restoring circadian rhythms in individuals with 
insomnia and jet lag, further supporting the role of melatonin in regulating 
circadian rhythms (Zisapel, 2001). Agomelatine has a high affinity for 5-HT2C 




mediated through these receptors (Millan et al., 2003; Papp et al., 2003). Altered 
5-HT2C receptor levels have been implicated in depression (Riedel et al., 2002).  
Rats, which are nocturnal animals prefer dim light as opposed to bright light 
(Castelhono-Carlos, 2009). This is also supported by the findings that albino rats 
adjust better to low light intensity that is below 100 lux than to higher light intensity 
(Blom et al., 1995). Similarly, rats exposed to 10 days of CCL displayed decreased 
hypothalamic CRF-like immunoreactivity CRF-L, decreased CR of plasma CORT 
and increased plasma ACTH (Fischman et al., 1988). Similarly, Mohawk et al. 
(2007) showed that one hour of light exposure at night resulted in elevated CORT 
levels with ACTH levels increasing after 15 minutes of exposure. However, light 
exposure during the day did not result in any changes in glucocorticoid levels. As a 
result the authors concluded that light exposure during the dark period directly 
affected the HPA axis leading to the secretion of glucocorticoids, in a manner 
resembling the secretion of glucocorticoids under a stressful situation. These data, 
suggest that continuous lighting during the dark acts as a stressor.  
 It is well known that disruption of the HPA axis also predisposes animals to 
anxiety and depressive-like behaviours (Plotsky and Meaney, 1993). CCL has 
been shown to induce anhedonic, anxiety- and depressive-like behaviours (Ma et 
al., 2007; Martynhak et al., 2011; Tapio-Osorio et al., 2013). Wistar rats that were 
subjected to 8 weeks of CCL showed a disrupted CR of locomotor activity and 
plasma melatonin secretion (Tapio-Osorio et al., 2013). CCL also caused 
increased sucrose intake and anxiety-like behaviours in the OFT as well as 
elevated levels of CORT (Tapio-Osorio et al., 2013). Furthermore, it was shown 
that 7 days of continuous light from embryonic day 20 to postnatal day 4 resulted 
in high anxiety-like behaviours in the OFT as demonstrated by more time spent in 
the outer zone than in the inner zone of the open field (Roman and Karlsson, 
2013). These studies provide substantial evidence that CCL is a stressor; this is 
demonstrated by the altered HPA axis activity as well as the manifestation of 
depressive- and anxiety-like behaviours in animals in adulthood (Ma et al., 2007; 




Furthermore, light exposure has also been associated with anhedonic behaviours 
and manic-like behaviours in rats (Martynhak et al., 2011). For example, 3 weeks 
of light exposure during adulthood decreased sucrose preference, suggesting 
anhedonic-like behaviours (Martynhak et al., 2011). However, combination of light 
exposure during the neonatal period and adulthood reversed the decreased 
sucrose preference. Light exposure during neonatal period protected rats from 
developing the anhedonic behaviours caused by additional exposure to light in 
adulthood (Martynhak et al., 2011). Similarly, light exposure during the neonatal 
period prevented abnormal circadian rhythms caused by more than 3 weeks of 
light exposure during adulthood (Cambras et al., 1998; Canal-corretger et al., 
2001). Moreover, it was revealed that 12 days of light exposure during the 
neonatal period was the minimum number of days required to develop a strong 
circadian rhythm in rats exposed to additional lighting in adulthood (Canal-
corretger et al., 2001).  Therefore, the strong circadian rhythm as a result of light 
exposure during the neonatal period protected rats from developing the 
anhedonic-like behaviours induced by continuous lighting in adulthood (Cambras 
et al., 1998; Canal-corretger et al., 2001; Martynhak et al., 2011). These findings 
suggest that rats exposed to continuous lighting only in adulthood are susceptible 
to developing anhedonic behaviours due to the inability of the circadian rhythms to 
adjust to the change in photoperiod, providing further evidence to support CCL as 
an additional stressor and as a suitable model to study depression.  
Increased sucrose preference and hyper locomotion phenotypes in animals have 
been proposed to model the manic spectrum of bipolar disorder (Flaisher-Grinberg 
et al., 2009a, 2009b). Increased sucrose preference was observed in Black Swiss 
mice; a mouse strain displaying manic related behaviours such as 
hyperlocomotion (Flaisher-Grinberg et al., 2009a). Martynhak et al. (2011) also 
found increased locomotor activity and sucrose preference in rats subjected to 3 
weeks of constant light during the neonatal period, suggestive of displaying manic-
like behaviours.  These findings suggest that the timing of light exposure is an 
important factor when choosing a stress model, as different behavioural 
phenotypes are reported to result from exposure to CCL during various 
developmental stages of the animal. For this study, rats were only subjected to 3 




since light exposure during adulthood leads to anhedonic and depressive-like 
behaviours. As opposed to light during the neonatal period which results in manic-
like behaviours (Ma et al., 2007; Martynhak et al., 2011; Tapio-Osorio et al., 2013). 
The abnormal phenotypes induced by CCL suggest that CCL exposure at certain 
developmental time points might share a similar pathophysiology as 
bipolar/depressive disorder. Decreased extracellular signal-related kinase (ERK) 
signalling is often implicated in bipolar disorders and administration of a mood-
stabiliser (valproate) reverses the decreased ERK signalling (Hao et al., 2004). 
Similarly, deficiencies in ERK signalling have also been implicated in the 
pathophysiology of depression (Haung and Reichardt, 2001; Feng et al., 2003; 
Karege et al., 2005). ERK plays a major role in regulating the expression of BDNF 
and reduced ERK is associated with reduced BDNF levels which are often 
implicated in depression (Haung and Reichardt, 2001; Feng et al., 2003; Karege et 
al., 2005).  Therefore, the presence of anhedonic, anxiety- and depressive-like 
behaviours after light exposure suggest that CCL is a stressor and that it is 
implicated in the pathophysiology of depression (Canal-corretger et al., 2001; Ma 
et al., 2007; Flaisher-Grinberg et al., 2009a; Martynhak et al., 2011; Tapio-Osorio 
et al., 2013). Hence, CCL was chosen as an additional stressor in order to 
elucidate the underlying mechanisms implicated in the pathophysiology of 
depression. 
1.9 Dopamine and depression 
Dopamine (DA) is a catecholamine and a neurotransmitter that is involved in 
signalling processes between neurons (Sarkar et al., 2010). DA is produced in the 
cytoplasm of presynaptic neurons from the amino acid phenylalanine and tyrosine 
(Dunlop and Nemeroff, 2007). Most of the dopaminergic neurons in the brain are 
located in brainstem nuclei; retro-rubro field, substantia nigra pars compacta and 
ventral tegmental area (VTA) (Dunlop and Nemeroff, 2007). DA exerts its effect on 
postsynaptic neurons through its interactions with one of five subtypes of DA 
receptors which are divided into two groups (Dunlop and Nemeroff, 2007). The 




the second group, the D2 family consists of D2, D3 and D4 subtypes. In the CNS, 
circuits containing DA are important regulators of the following functions; 
motivation, regulating locomotion, cognition, emotion, concentration and ability to 
experience pleasure (Ikemoto and Panksepp, 1999; McClure et al., 2003; 
Shirayama and Chaki, 2006; Dunlop and Nemeroff, 2007).   
There are three major dopaminergic pathways which innervate various cortical and 
subcortical structures namely; nigrostriatal, tuberoinfundibular and 
mesocorticolimbic pathway (Dunlop and Nemeroff, 2007; Shirayama and Chaki, 
2006). The nigrostriatal pathway arises from the substantia nigra pars compacta 
and projects to the dorsal striatum (caudate and putamen) (Dunlop and Nemeroff, 
2007). This pathway plays a major role in regulating motor and non-motor 
functions such as executing and planning movement as well as cognition (Dunlop 
and Nemeroff, 2007). The tuberoinfundibular pathway originates from the arcuate 
nucleus of the hypothalamus and projects to the median eminence of the 
hypothalamus. Functionally, this pathway plays an important role in controlling the 
release of growth hormone from the anterior pituitary. The mesocorticolimbic 
pathway is made up of numerous brain areas such as the VTA, ventral striatum 
(nucleus accumbens, NAc), hippocampus, motor cortex, amygdala and septum. 
This pathway controls reward-related behaviours, motivation and ability to 
experience pleasure as well as locomotor activity (Ikemoto and Panksepp, 1999; 
Shirayama and Chaki, 2006; Dunlop and Nemeroff, 2007).  
The mesolimbic dopaminergic system stimulates the NAc, amygdala and septum 
(Ikemoto and Panksepp, 1999; Shirayama and Chaki, 2006; Dunlop and Nemeroff, 
2007). Due to the robust findings of anhedonia in depression, it has been 
proposed that reduced motivation and decreased energy levels in depressed 
individuals suggest that the NAc and VTA are implicated in the pathophysiology of 
depression (Ikemoto and Panksepp, 1999). Of importance is accumbal DA 
release, as this region regulates important functions such motivation, reward, 
motor function and learning (Shirayama and Chaki, 2006; Koob and Bloom, 1988; 




The shell and core are the two subregions of the NAc comprising of the ventral 
striatum. Dopaminergic activity in the NAc is influenced by many molecules such 
as glutamate, 5-HT, gamma-aminobutyric acid (GABA), acetylcholine, and 
neuropeptides. The NAc receives dense glutamatergic innervations from the PFC, 
amygdala and hippocampus, the same brain regions that are involved in HPA axis 
regulation in response to stress (Rosso and Nestler, 2013). Therefore, these 
findings suggest that accumbal DA release is implicated in stress regulation. 
Indeed, accumbal DA release is highly susceptible to stress and abnormal DA 
release in the NAc causes anhedonia in both human and animal models of 
depression (Wilner et al., 1992; Yadid et al., 2001). For example, DA levels are 
depleted in the NAc of animals experiencing learned helplessness and this can be 
prevented by administrating a DA agonist (Anisman et al., 1979). 
Reports suggest that short-term exposure to various forms of stress enhances 
accumbal DA release (Kalivas and Duffy, 1995; Tidey and Miczek, 1996). 
However, long-term exposure to different types of unavoidable stressors 
decreases DA release in the NAc shell (Di Chiara et al., 1999; Scheggi et al., 
2002). For example, mice subjected to unavoidable foot shock showed decreased 
DA release in the NAc in contrast to mice subjected to escapable foot shock which 
showed increased DA release in the NAc (Cabib and Pugusi-Allegra, 1994). 
Similarly, DA reuptake inhibitors were shown to treat depression by increasing DA 
concentration in NAc (Garattini, 1997). Ichikawa et al. (1998) showed that chronic 
administration of the antidepressant imipramine and DA agonist, amphetamine, 
resulted in increased extracellular dopamine levels in the NAc. In a validated 
genetic model of depression, the Flinders Sensitive Line (FSL) rats showed 
deficits in 5-HT-induced DA release in the NAC which was restored by 
antidepressant treatment (Moreo et al., 1996; Ichikawa and Meltzer, 1999; Di 
Matteo et al., 2001; Zangen et al., 2001; Dremencov et al., 2004).  
These findings provide substantial evidence to support the role of DA in 
depression, in particular accumbal DA release (Wilner et al., 1992; Yadid et al., 
2000). Moreover, the fact that accumbal DA interacts with many neurological 
systems such as the 5-HT, opioid and orexinergic systems justifies the importance 




Berridge, 2000; Di Matteo et al., 2001; Dremencov et al., 2004; Baldo and Kelley, 
2007; Nocjar et al., 2012). DA release in the NAc after MS and CCL exposure was 
therefore investigated in an attempt to provide further insight into the 
pathophysiology of depression. The effects of MS are potentiated by additional 
stressors such as CCL or restraint stress which impair spatial memory and induce 
depressive- and anxiety-like behaviours in rodents (Ma et al., 2007; Marais et al., 
2008; Eiland and McEwen, 2012). Hence for this study CCL exposure was chosen 
to exacerbate MS-induced DA release. 
1.10 Serotonin (5-HT) and depression 
About 50% of 5-HT cells in the rat brain are found in the DRN which is located in 
the brainstem (Azmitta and Segel, 1978; Jacobs and Azmitta, 1992). 5-HT exerts 
its effects through several 5-HT receptors made up of different subtypes that 
belong to the family of G-protein coupled receptors except 5-HT3R, which is a 
ligand-gated ion channel. Examples of 5-HT receptor subtypes include 5-HT1AR, 5-
HT2AR, 5-HT2CR, and 5-HT4R, (Paul and Lowry, 2013).  Functionally, 5-HT is 
involved in arousal (sleep and wake cycle), regulation of mood and emotional 
behaviours, motor function and appetite (Owen and Nemeroff, 1994; Di Matteo et 
al., 2008). 5-HT mediates dopamine release both in the PFC and NAc (Di Matteo 
et al., 2008). Furthermore, interaction of 5-HT and dopamine, in particular in the 
NAc has been implicated in mechanisms underlying substance abuse and 
depression (Waselus et al., 2011). 
The DRN innervates many brain regions that respond to stressors (Molliver, 1987; 
Peyron et al., 1998). The 5HT-ergic system is implicated in many mental disorders 
including anxiety and depression (Owen and Nemeroff, 1994; Blier and de 
Montigny, 1999; Mann, 1999). Moreover, reduced levels of 5-HT or its precursor 
(tryptophan) are implicated in the pathophysiology of depression, panic and 
obsessive-compulsive disorders, OCD (Meltzer and Lowy, 1987; Owen and 




Different patterns of 5-HT responsivity following various forms of stress are 
observed.  Serotonin levels can increase, decrease or have no response following 
exposure to different stressors such as restraint stress, forced swimming and 
motor activity (Kirby et al., 1995; Kirby and Lucki, 1997; Adell et al., 1997). In a 
validated genetic model of depression, FSL rats showed a decrease in 5-HT 
turnover in the NAc compared to the Flinders Resistant Line (FRL) rats (Zangen et 
al., 1997). Also in FSL, it was shown that dopamine release was altered after 
blocking 5-HT2C receptors (Dremencov et al., 2005). Similarly, changes in the 
concentration of 5-HT have also been noted in the MS model (Mathew et al., 
2001). Increased 5-HT2R density in the brains of depressed suicide victims have 
been reported and antidepressant treatment decreases 5-HT2 receptor density in 
the brain (Mongeau et al., 1997; Rosel et al., 2000). Moreover, agomelatine, a 5-
HT2CR antagonist, induces antidepressant like effects (Loo et al., 2002). Low 
levels of extracellular DA levels in the NAc of FSL were reversed by local 
administration of a 5-HT2CR antagonist (Dremencov et al., 2005). Antidepressants 
may regulate dopamine release through activation of 5-HT receptors (Blier and 
Bergeron, 1995; Briner and Dodel, 1998; Ichikawa and Meltzer, 1999; Di Matteo et 
al., 2001; Dremencov et al., 2004).  
Pharmacological treatments are aimed at enhancing 5HT-ergic neurotransmission 
in order to improve depressive moods (Kent et al., 2002; Blier and de Montigny, 
1994). This is achieved by blocking 5-HT transporters from taking up 5-HT into the 
presynaptic terminal and thus resulting in increased concentration of 5-HT in the 
synaptic cleft (Khwawam et al., 2006; Danese and Pariente, 2008; Paul and 
Lowry, 2013). This enhances or lengthens exposure of 5-HT to postsynaptic 5-HT 
receptors thereby increasing 5-HT neurotransmission, which has been shown to 
be beneficial in treating depression (Di Matteo et al., 2001; Dremencov et al., 
2004; Khwawam et al., 2006; Danese and Pariente, 2008). 
Furthermore, 7 day treatment with nefazodine (5-HT2CR antagonist), a fast onset 
antidepressant, normalised immobility time in the FST in FSL rats compared to a 
classical antidepressant, desipramine (Dremencov et al., 2004). Moreover, 
nefazodine caused a significant increase in dopamine levels in the NAc in FSL rats 




(Dremencov et al., 2004). It has been consistently shown that nefazodine 
enhances 5-HT by blocking 5-HT2CR levels that are often increased in depression 
thereby causing a dopamine release in the NAc (Moreo et al., 1996; Sanchez and 
Hyttel, 1999; Dremencov et al., 2004). Therefore enhanced 5-HT levels either by 
normalising or a down-regulating 5-HT2CR level improves depressive-like 
behaviours (Moreo et al., 1996; Dremencov et al., 2004). 
These studies provide evidence that the 5HT-ergic system is involved in 
depression. For this study the hypothalamus and PFC were chosen to investigate 
5-HT levels after MS and CCL due to the fact that the both PFC and hypothalamus 
form part of the HPA axis stress system and are most vulnerable to the effects of 
early life and adult stress exposure (Lupien et al., 2000; Geoffroy et al., 2006; 
Albers et al., 2008; Lupien et al., 2009). Furthermore, the SCN which is part of the 
hypothalamus plays a crucial role in controlling stress responses; more specifically 
in regulating glucocorticoid release and their circadian rhythms (Campbell and 
Dawson, 1990; Redlin, 2001; Liu et al., 2006; Bao et al., 2008). Most importantly, 
5-HT also interacts with other brain regions implicated in depression, such as the 
NAc, further supporting the importance of studying 5-HT levels in depression after 
MS and CCL exposure (Ichikawa and Meltzer, 2000; Di Matteo et al., 2001; 
Dremencov et al., 2004). 
1.11 Opioid and depression  
The opioid peptide system is made up of endorphins, enkephalins, and dynorphins 
that act on three receptor subtypes, namely MOR, delta-opioid (DOR) and kappa-
opioid (KOR). Opioid peptides and receptors are widely distributed in several brain 
regions in the brain, including the limbic system (amygdala, NAc, and 
hypothalamus) and pituitary glands to regulate many biological processes of which 
include nociception, analgesia and feeding (Akil et al., 1998; Terenius, 2000; 
Przewlocki, 2002). The opioid system regulates many biological systems that 
respond to stress and these include behavioural, endocrine and autonomic 
nervous system (Calcagnetti and Holtzman, 1992; Watkins et al., 1992; 




The role of this system in controlling feeding is believed to be mediated through 
the NAc, an important brain area that is crucial for regulating motivation, reward 
process and pleasure seeking behaviours (Koob and Bloom, 1988; Ikemoto and 
Panksepp, 1999; Shirayama and Chaki, 2006). Injection of MOR and DOR 
agonists into the NAc and VTA evokes feeding (Kelley et al., 2002; Baldo and 
Kelley, 2007). In particular, MOR agonists function in the NAc is dependent on 
both the taste and the macronutrient of food; especially high energy food (Kelley et 
al., 2002; Baldo and Kelley, 2007). To lend support to MOR in regulating feeding, it 
was reported that MOR KO mice displayed decreased motivation to eat (Papaeo 
et al., 2007).The opioid system is also involved in the rewarding effects induced by 
drugs of abuse and sexual behaviours. For example, MOR KO mice were 
unresponsive to the effects of morphine and heroin during conditioned place 
preference (CPP) and self-administration (Matthes et al., 1996; Becker et al., 
2000; Marquez et al., 2007). Moreover, injection of a KOR antagonist into the NAc 
increased female directed behaviour to male rats (Matuszewich et al., 1995). 
These findings indicate that the NAc is an important brain region mediating opioid 
functions. 
The NAc is also implicated in the pathophysiology of depression (Ikemoto and 
Panksepp, 1999). Furthermore, it is often observed that depressed individuals 
show appetite and weight disturbance, reduced motivation and energy levels 
suggesting that the opioid system might be involved in aetiology of depression 
(Ikemoto and Panksepp, 1999; Pecina and Berridge, 2000; American Psychiatric 
Association, 2005). Individuals who committed suicide display enhanced MOR 
levels (Scarr et al., 2012). Furthermore, children whose mothers were taking 
opiates during pregnancy were reported to exhibit elevated anxiety and 
aggressiveness, providing evidence of the role of the opioid system in mood 
disorders (de Cubas and Field, 1993). 
Opioid receptors also regulate activity of the HPA axis, the KORs and DORs are 
highly expressed in the hypothalamic nuclei and decreased HPA axis activity was 
reported in MOR KO mice that were subjected to chronic restraint stress (Wang et 
al., 2002). MOR and KOR have been reported to mediate cardiovascular 




treatment with a MOR-antagonist prevents increases in blood pressure caused by 
stress exposure (Jimenez et al., 1990; Kapusta et al., 1989). Similarly, DOR 
activation by several agonists in rats and mice induces antidepressant-like effects 
in various behavioural tests of such as the FST and learned helplessness test 
(Tejedor-Real et al., 1995; Naidu et al., 2007). Administration of an opioid agonist 
induces preference for the open arms and increases exploration activity during the 
EPM test, indicative of anxiolytic behaviours (Broom et al., 2002; Terregrossa et 
al., 2006). DOR KO mice show increased anxiety levels and depressive-like 
behaviour whereas DOR agonists decreases immobility time in the FST (Broom et 
al., 2002; Terregrossa et al., 2006). Moreover, KOR antagonists decrease 
immobility time in the FST whereas KOR agonists increase immobility time in the 
FST (Mague et al., 2003). 
The opioid system has also been implicated in maternal care and it has been 
found that MOR function in maternal care is important for maintaining stress 
responses and stress-related disorders throughout life (Liu et al., 1997). Variants 
within the MOR gene are associated with the quality of parental attachment in 
primates and humans (Barr et al., 2008; Copeland et al., 2011). For example, 
increased ultra sound vocalizations as a result of MS are reduced in MOR KO 
mice, suggesting that the MOR activity is implicated in mood and stress regulation 
(Moles et al., 2004). Similarly, MOR KO mice are less anxious; exhibit reduced 
depressive-like trait features than wild-type mice (Filliol et al., 2000; Yoo et al., 
2004).  In contrast, reduced MOR levels in the NAc were reported after MS which 
were restored by CCL exposure, suggesting that MS induces depressive like 
behaviours (Dimatelis et al., 2012). 
It is evident that the opioid system is involved in the pathophysiology of 
depression. However, the contradictory findings on the function of MOR in 
depression suggest that there is little known about the exact function of this 
receptor in the pathophysiology of depression (Filliol et al., 2000; Yoo et al., 2004; 
Moles et al., 2004; Dimatelis et al., 2012). Hence, MOR protein levels in the NAc 
were chosen to investigate the aetiology of depression in rats subjected to MS and 
exposed to additional stressor (CCL). Of importance to note is the prominent role 




NAc (Liu et al., 1997; Shirayama and Chaki, 2006; Baldo and Kelley, 2007; 
Dimatelis et al., 2012). Further lending support for choosing the NAc as the brain 
region of interest for investigating MOR function in depression. 
1.12 Orexin and depression  
The orexinergic system is made up of approximately 50 000 - 80 000 orexin 
producing neurons in the human brain (Thannickal et al., 2000; Fronczek et al., 
2005; Peyron et al., 1998). The orexinergic system controls many functions, 
including feeding, reward process and HPA axis activity (de Lecea et al., 1998; 
Cason et al., 2010; Aston-Jones et al., 2010).  For example, orexin neurons in the 
VTA, amygdala and NAc are believed to regulate stress, reward and motivation 
and in the LH, orexin neurons regulate reward seeking behaviours (Fadel et al., 
2002; Harris and Aston-Jones, 2006). The orexinergic system includes orexin A 
and B peptides and orexin receptor 1 and 2 (OXR-1 and OXR-2) which are found 
in many parts of the brain (Sakurai et al., 1998; de Lecea et al., 1998; Lee et al., 
1999; Thannickal et al., 2000; Fronczek et al., 2005). Orexin A and B are 
hypothalamic neuropeptides found on the lateral hypothalamus (LH) where they 
are involved in regulating sleep, arousal and feeding (de Lecea et al., 1998; 
Sakurai et al., 1998; Sakurai et al., 2010; Cao and Guilleminauit, 2011). 
Orexin peptides bind specifically OXR-1 and OXR-2 receptors also known as 
hypocretin 1 and hypocretin 2 respectively (Sakurai et al., 1998). OXR1 binds very 
strongly to orexin A compared to orexin B (Sakurai et al., 1998). On the other hand 
OXR-2 binds both peptides with high affinity. OXR-1 mRNA is expressed in many 
brain regions such as the hippocampus and hypothalamus (e.g. PVN and 
ventromedial hypothalamus). OXR-2 mRNA is also expressed in many brain 
regions such as the cerebral cortex, hippocampus, DRN and many hypothalamic 
regions (Marcus et al., 2001; Sakurai et al., 1998). All of these areas have been 
implicated in the mediation of depressive-like behaviours. 
The orexinergic system is involved in several processes that are dysregulated in 




Guilleminauit, 2011). The sleep/wake cycle is regulated by the orexinergic system 
that receives input from the retina (Hattor et al., 2003). For example, abnormal 
circadian rhythms in orexin levels were found in the cerebrospinal fluid (CFS) in 
patients with SCN lesions (Deboer et al., 2003).  Despite the fact that orexin 
neurons do not receive direct input from the SCN, it is believed that the orexin 
neurons are extensively innervated by input coming from the bed nucleus of the 
stria terminalis (BNST), PVN and dorsomedial hypothalamus brain areas that 
receive direct input from the SCN (Sakurai et al., 2005; Yoshida et al., 2006). 
Sleep disturbances and circadian abnormalities are some of the symptoms 
reported in depressed patients and orexinergic system as an important regulator of 
the sleep and wake cycle has been implicated in dysregulated sleep/wake cycle 
during depression (Peyron et al., 2000; Salomon et al., 2003; Sakurai et al., 2010; 
Cao and Guilleminauit, 2011). Similarly, orexin deficiency causes sleep disorders 
and narcolepsy in both humans and animals which is indicative of the important 
role of this system in maintaining the sleep/wake cycle (Peyron et al., 2000; 
Thannickal et al., 2000; Salomon et al., 2003; Liu et al., 2011). Narcoleptic 
individuals show a significant decrease in the number of orexin neurons (90%) as 
well as displaying decreased levels of orexin A in cerebrospinal fluid (Peyron et al., 
2000; Mignot et al., 2002; Salomon et al., 2003; Liu et al., 2011). Furthermore, 
polymorphisms within OXR-1 gene were associated with increased risk for 
developing unipolar disorder (Rainero et al., 2011). Individuals with anxiety 
accompanied by panic attacks have increased levels of orexin in the CSF 
(Johnson et al., 2010).  
In response to stress, orexin neurons receive input from the limbic system and are 
also various forms of stress such as foot shock, food deprivation and social defeat 
stress (Sakurai et al., 1998; Ida et al., 2000; Winsky-Sommerer et al., 2004; 
Sakurai et al., 2005; Yoshida et al., 2006 Berridge et al., 2010).  During stress, 
orexin neurons also regulate HPA axis activity by innervating CRH neurons in the 
PVN of the hypothalamus (Winsky-Sommerer et al., 2004). It is believed that the 
relationship between the CRF system and the orexinergic system might be useful 





Mice subjected to unpredictable chronic mild stressors (UCMS) displayed 
decreased levels of cell proliferation and neurogenesis in the hippocampus which 
was reversed by chronic fluoxetine treatment and dual orexin receptor (OXR-1 and 
OXR-2) antagonist (Nollet et al., 2012). Furthermore, both fluoxetine and dual 
orexin (OXR-1 and OXR-2) antagonist administration improved depressive-like 
behaviours, suggesting that inhibition of the orexinergic system has 
antidepressant-like effects (Nollet et al., 2012).  
Nocjar et al. (2012) reported reduced levels of orexin in the VT, mPFC and 
hypothalamus of rats subjected to a social defeat model. Furthermore, these rats 
displayed a decreased sucrose preference scores when matched to controls, 
which was attributed to the decreased levels of orexin in the dopamine reward 
system (Nocjar et al. (2012). In agreement with these findings, decreased orexin 
function was also associated with diminished reward seeking behaviour, indicating 
anhedonic behaviour (Aston-Jones et al., 2002).  Moreover, a genetic animal 
model of depression, Wistar-Kyoto rats, exhibited an 18 % decrease in the number 
of orexin neurons compared to controls (Allard et al., 2004). In contrast, FSL rats 
had high number of orexin neurons in the hypothalamus including increased 
immobility in the FST (Mikrouli et al., 2011). The discrepancies in these studies 
might due to the fact that Mikrouli et al. (2011) used female rats in contrast to the 
male rats that were used by Allard et al. (2004). Furthermore, the female rats were 
subjected to forced swimming (stressor) before the stereological analysis of orexin 
neurons which is most likely to have contributed the increased number of orexin 
neurons reported in this study (Mikrouli et al., 2011).    
These findings provide substantial evidence of the role of the orexinergic system in 
depression. It is well established that depressed individuals exhibit many 
depressed moods (altered sleep, changes appetite, and anhedonia) that are also 
regulated by this system, indicating that the orexinergic system is implicated in the 
pathophysiology of depression. Despite the improvement in understanding the 
function of the orexinergic system in depression, the contradictory findings 
reported on the role of orexin peptides and receptors suggest that more research 
is required to provide more insight on the function of this system in depression 




orexin peptides (A and B) and orexin receptors (OXR-1 and OXR-2) were chosen, 
to investigate the role of the orexinergic system in rats subjected to MS and 



















Exposure to CCL for 3 weeks will result in changes in glutamate- and potassium-
stimulated [3H]dopamine release, 5-HT levels, MOR-1 levels, orexin (A and B) and 
OXR-1 and 0XR-2 levels in  the brains of MS rats (Figure 1.5).  
 
Figure 1.5: Hypothesis. It is hypothesised that MS exposure (for 2 weeks) starting from 
postnatal day (PND) 2 during a critical stage (i.e. postnatal period) in brain development 
will alter the HPA axis activity. As the hippocampus, frontal cortex and amygdala; 
important brain areas making up the stress system are still maturing during this period, 
suggesting that the HPA axis is vulnerable to the effects of stress exposure. Moreover, an 
altered HPA axis might impair SCN activity as these systems influence each other in 
responding to stress effects. Furthermore, MS exposure is most likely to impair dopamine 
system, serotonin (5-HT), opioid system and orexin system, brain systems that are 
implicated in stress regulation.  Alterations to these systems predispose the brain to 
additional stressors later in life. As a result, CCL exposure is likely to exacerbate the 
effects of MS thereby changing dopamine release in the NAc, 5-HT levels in the 
hypothalamus and prefrontal cortex (PFC) and µ-opioid receptor (MOR) levels in the NAc. 
Orexin peptides (A and B) in the hypothalamus and orexin receptors in the PFC are most 
likely to be affected by additional exposure to CCL. Furthermore, SCN activity is also 
vulnerable to the effects of additional CCL exposure suggesting that biological functions 
that are dependent on SCN activity might also be altered by CCL exposure thereby 





1.14 Aims and objectives 
This study aims to explore the effects of additional CCL exposure in an MS model 
by: 
 Measuring glutamate- and potassium-stimulated [3H]DA release in the NAc in the 
four experimental groups; non-maternally separated (NMS) rats, NMS rats 
subjected to CCL,  MS rats and MS rats exposed to CLL. 
 
 Testing the effects of CCL on 5-HT levels in the hypothalamus and PFC 
 
 Measuring MOR-1 levels in the NAc 
 






CHAPTER 2: METHODOLOGY 
2.1 Animals 
A total of 112 male Sprague Dawley (SD) (Rattus Norvegicus) comprising of 28 
rats per group; NMS rats, NMS rats exposed to 3 weeks of CCL, MS rats and MS 
rats subjected to CCL were used for this study. Half of each experimental group 
(n=14/group) was used for the in vitro superfusion experiments and the rest 
(n=14/group) was used for biochemical analysis (Figure 2.1). All experimental 
procedures conducted were approved by the Health Sciences Faculty Research 
Ethics Committee of the University of Cape Town (Ethics reference number 
021/057) (Appendix A). The date of birth was regarded as postnatal day zero 
(PND 0). All the animals were kept under standard conditions which included a 
constant room temperature (23  ± 1 °C), tap water and  rat chow  was available ad 
libitum for the duration of the experiment. A 12 h/12 h L/D cycle was maintained 
(lights on from 06:00 and off at 18:00) except during the CCL procedure where a 
12 h/12 h L/L cycle was maintained. 
Rats were housed not more than four in Plexiglas cages with sawdust as bedding. 
All rats were housed in the same colony room separate from the experimental 





Figure 2.1: Overview of experimental procedures. Four experimental groups out of 
which two groups; non-maternally separated (NMS, n=28) rats and maternally separated 
(MS, n=28) rats were exposed to CCL (24 hr L/L cycle) for 3 weeks (from postnatal day, 
PND, 42-63) during adolescence and the remaining two groups; NMS (n=28) rats and MS 
(n=28) animals were not subjected to CCL. At PND 80, all the rats were decapitated and 
half of the rat brains (n=14) from each experimental group were used to dissect out the 
designated brain areas employed for in vitro superfusion and biochemical analysis. 
 
2.2 Maternal Separation (MS) model  
On PND 2, pups were sexed and culled to 8 rats per litter (Figure 2.2). Male rats 
were used in the study as it has been previously demonstrated that MS affects the 
HPA axis activity of male rats and thus increases the likelihood of altering the HPA 
axis activity (Hout et al., 2001; Ladd et al., 2004; Veenema et al., 2006). Equal 
litter sizes ensured that pups get adequate nutrition from their mothers. The MS 
paradigm was performed according to the procedure established by Ladd et al. 
(2000) with slight modifications. The mother was removed from the litter and 
placed in a different cage whilst the pups remained in the home cage. The cage of 
the mother remained in the housing satellite facility and the home cage containing 
pups was taken to a different room. MS was performed for 3 hours daily, from 




MS, pups were kept under infrared light with temperatures kept between 30 - 33 
°C in order to prevent hypothermia. After 3 hours of separation, the pups were 
returned to the animal housing satellite facility and the dam was returned to the 
home cage with the pups and reunited with her pups. From PND 15, pups were 
reared under normal conditions (Figure 2.2).  
The cages were cleaned twice a week and care was taken to ensure that pups 
were not handled as handling reverses MS-induced changes (Levine, 1957; 
Fernandez-Teruel et al., 2002; Kiosterakis et al., 2009).  Neonatal handling has 
been shown to induce a resilient HPA axis, thus increasing the ability to cope and 
adapt to stressful events (Levine, 1957; Fernandez-Teruel et al., 2002; Kiosterakis 
et al., 2009).  
NMS rats were not separated from their mothers instead they were reared under 
standard conditions. 
2.3 CCL exposure  
Two groups of male SD rats, half of the NMS and MS rats were subjected to CCL 
for 3 weeks (PND 42 to PND 63). The CCL exposure was performed in a dark 
room where the home cage was placed under lights with light intensity ranging 
between 100-120 lux generated by a 40W bulb. After the CCL exposure rats were 
returned to the animal housing facility with standard lighting conditions; 12 h/12 h 
light/dark cycle (lights on at 06:00 and off at 18:00). At PND 80 all the animals 










Figure 2.2: Timeline of experimental procedures. Timeline of the experimental 
procedures conducted from postnatal day (PND) 0 to 80. Abbreviations: Maternal 
separation (MS), CCL (chronic constant light) and enzyme-linked immunosorbent 
assay (ELISA). 
 






An in vitro superfusion technique that has been standardised in our laboratory 
prior to the present study was employed to measure glutamate- and potassium-
stimulated [3H]DA release from NAc slices (Russell and Wiggins, 2000; Howells 
and Russell, 2008; Sterley et al., 2012) (Figure 2.3). On PND 80 rats were killed 
by decapitation between 09h00-12h00.  After decapitation the brain was rapidly 
removed and placed in ice-cold Krebs buffer for 20 minutes. The chilled brains 
were sliced coronally with a Mcllwain tissue chopper (Figure 2.4). The NAc shell 
and core were dissected from the two 0.9 mm2 brain slices that contained the NAc. 
The tissue was chopped into 0.3 X 0.3 mm sections and suspended in Krebs 
 
 See the Appendix section for the list of buffers, reagents and additional 
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buffer for 10 minutes at 37 °C (Appendix B1). The Krebs buffer was aerated with 
carbogen (95 % O2 / 5 % CO2) for the duration of the experiment. 
The NAc core and shell tissue slices were then incubated for 15 minutes with 
0.125 µM [3H]DA (2.67 µl – [7-3H], 9.25 MBq/ ml, 21.2 Ci/mmol, Amersham 
biosciences UK limited) in the presence of 5.67 mM ascorbic acid to reduce the 
metabolism of [3H]DA. This ensures that the labelled [3H]DA is taken up into the 
dopaminergic terminals in the NAc slices. Immediately after the incubation period, 
equal portions of the tissue were transferred to superfusion chambers and 
continuously perfused with Krebs buffer at 37 °C. Each experiment consisted of 2, 
3 or 4 rats. The tissue from each rat was distributed over four superfusion 
chambers (Figure 2.5). Two out of the 4 chambers per rat were loaded with tissue 
from the NAc shell and the other 2 chambers were loaded with tissue from the 
NAc core. This was carried out so that there was a duplicate determination of 
[3H]DA release from each subdivision of the NAc from each rat. DA release was 
induced either by exposure to 1 mM glutamate or 25 mM potassium stimulation at 
specific time points during the experiment (Figure 2.5). 
The superfusion experiment was composed of the following components; two 45-
minute washes to remove excess radioactive material and to achieve a stable 
efflux of radioactivity (Figure 2.5). This was followed by two 5-minute fractions of 
eluate to establish baseline release of [3H]DA. The third 5-minute was performed 
by removing the inlet tubes from the Krebs buffer into the 1 mM glutamate 
containing Krebs buffer for glutamate stimulation. Glutamate stimulation was 
achieved by exposing the tissue slices to 1 minute pulse of the 1 mM glutamate to 
stimulate [3H]DA release from the NAc shell and core (Figure 2.5).  After the 1 
minute glutamate stimulation, the inlets tubes were returned to the Krebs buffer for 
the remaining 4 minutes. An additional three 5-minute fractions of eluate were 
collected to re-establish the baseline of [3H]DA release after glutamate stimulation 
(Figure 2.5). This was followed by a 25 mM potassium stimulation which was 
achieved by removing the inlet tubes from the Krebs buffer to potassium 
containing Krebs solution for 1 minute. For the remaining 4 minutes, the inlet tubes 
were returned back to the Krebs buffer to collect a 5-minute fraction of [3H]DA 




re-establish a baseline of [3H]DA release following the potassium stimulation. At 
the end of these two 5-minute fractions the superfusion chambers were allowed to 
drip dry before collecting the pellet (cotton wool containing radio-labelled tissue 
slices) (Figure 2.5).   
The pellet was collected into a vial containing 1 ml of 0.1 M of NaOH which was 
added in order to break the tissue slices thus releasing the remaining endogenous 
[3H]DA. The eluate and pellets were left overnight and counted with a beta counter 
the next day. 
Before samples were counted, 3.4 ml of scintillation fluid was added to each vial in 
order to measure the radioactivity labelled DA in the samples. The function of the 
scintillation fluid is to transfer the energy of the beta particles that are emitted by 
the radioactive isotope [3H] of samples to the scintillation analyser (Kessler, 1991).  
After the addition of the scintillation fluid, radioactivity in the 5-minute fractions of 
eluate and radioactivity remaining in the tissue slices at the end of the experiment 
were determined using a Packard 1900 TRI-CARB liquid scintillation analyser. The 
measured radioactivity (disintegrations per minute, DPM, 10 minutes per sample) 
in each vial was determined using the quench curve generated from the known 
radioactivity of the quenched standard samples (Appendix B2). Briefly, the quench 
curve was generated by plotting the quench values of the standards, represented 
by the transformed external standard spectrum (tSIE) against the percentage 
efficiently. The percentage efficiency refers to how efficient the energy of the beta 
particles is transferred to the scintillation analyser (Kessler, 1991). From this, the 
DPM of the radio-labelled samples was quantified. The DPM values of the 
samples where within the quench curve of the standards, between 200-400 tSIE 
values (Appendix B2). 
To correct for the variability in the amount of tissue in the superfusion chambers, 
radioactivity in each eluate fraction was expressed as a percentage of the total 
amount of radioactivity present in the slices at the time of release of that 5 minute 
fraction. To determine the glutamate- or potassium-stimulated [3H]DA release 
relative to the baseline, the percentage release in the preceding baseline fraction 




Figure 2.3: In Vitro superfusion setup. The setup of the in vitro superfusion technique used to measure glutamate- and potassium-
stimulated [3H]DA release in the NAC core and shell. 
Superfusion chambers 
Outlet tubes 






(Adapted from paxinos and Watson, 1986)  
Figure 2.4: A dissection diagram of the NAc core and shell. Following decapitation, 0.9 mm2 coronal slices of the brain were obtained 
using a Mcllwain tissue chopper. The two slices containing the NAc were used to dissect the NAc shell and core. The remaining olfactory 
bulb and surrounding tissue was removed with a blade as indicated by cut number 1. The corpus callosum, NAc (core and shell) and anterior 
commissures were used as markers to determine cut number 2, the slice was then cut in half (3) in order to make a precise dissection of the 
NAc core and shell. The brain tissue medial to the NAc was removed (cut number 4). Cut numbers 5 and 6 indicate how the NAc core and 







Figure 2.5: A schematic diagram showing the in vitro superfusion experiment set up. Two 45-minute washes were established to 
remove excess radioactive material. Number 1 and 2 are two 5-minute fractions of [3H]DA release for baseline recordings. Number 3 
represents 5-minute fraction of [3H]DA release divided into 1-minute pulse of 1 mM glutamate-stimulation and remaining 4 minutes of  [3H]DA 
release in Krebs buffer solution. Number 4 to 6 represent 5-minute fractions of [3H]DA release collected to re-establish baseline following the  
1mM glutamate stimulation. Number 7 represents 5-minute fraction of [3H]DA release consisting of 1-minute 25 mM potassium stimulation 
and the remaining 4 minutes of Krebs buffer solution. The last two of 5- minute fractions (numbers 8 and 9) were collected to re-establish 
baseline [3H]DA release following the 25 mM potassium stimulation. Number 10 represents a time point in which the perfusion pump was 
switched off to allow the superfusion to drip dry before the pellet was collected.  The collection of the pellet to measure the total radioactive 





Figure 2.6: An example of the 5-minute fractions of eluate collected during the in 
vitro superfusion experiment. Number 3 on the x-axis contained glutamate-stimulated 
release of radioactivity and number 7 contained potassium-stimulated release of 
radioactivity. The remaining 5- minute fractions are baseline recordings of [3H] DA release 





2.5 Biochemical Analysis 





On PND 80 rats were killed by decapitation between 09h00-12h00. After 
decapitation brain tissue was rapidly removed and placed in cold saline (0.9 % 
NaCl) solution. The whole hypothalamus was dissected manually using surgical 
instruments and this was followed by a dissection of the PFC. PFC was dissected 
from coronal slices (0.9 mm2) obtained with a Mcllwain tissue chopper. The tissue 
samples were stored in liquid nitrogen until analysed.  
Hypothalamus and PFC tissue was weighed and diluted with RIPA buffer 
(Appendix C1). Protease inhibitor cocktail (2 µL per 1 ml of RIPA buffer, Thermo 
Scientific, Rockford, USA) was added to inhibit protein degradation.  Furthermore, 
1 mM EGTA was added to the buffer solution to assist tissue extraction by 
disrupting protein complexes that contain proteins of interest (Tria et al., 2013).  
RIPA buffer (1 ml) was added per 50 mg of hypothalamus and PFC sample. 
Proteins were then solubilised by sonicating the samples for 10 seconds and 
mixing them on a vortex for another 10 seconds. After which, they were then left to 
stand on ice for 20 minutes.  After 20 minutes, the samples were centrifuged at 
17200 x g for 30 minutes at 4 °C and the supernatant was collected and kept 
overnight at -80 °C.   
The next day, all the samples were centrifuged again at 12000 x g for 10 minutes 
at 4 °C. Twenty µl from the samples and from each of the two controls (1 and 2) 
were added to a glass tube. A further 100 µl of Assay buffer and 25 µl of acylation 
reagent (Appendix C2) were added to the glass tube and mixed using a vortex 
 See the Appendix section for the list of buffers, reagents and 






mixer. The glass tubes were then covered and incubated in the water bath for 15 
minutes at 37 °C. Following the incubation period, 2 ml of the Assay buffer was 
added to each glass tube and mixed on a vortex mixer. The samples were then 
centrifuged for 10 minutes at 1500 x g. Immediately after centrifugation, 50 µl of 
each standard (which were already acetylated), control and sample was added to 
the wells of the microtiter plate which was coated with a primary antibody, anti-
rabbit antiserum produced in goat (Appendix C2).  This was followed by addition of 
50 µl of biotinylated 5-HT and a further 50 µl of rabbit secondary antibody was also 
added into the microtiter plate for the production of the antibody-antigen complex. 
This procedure induces a competitive reaction whereby there is a competition 
between biotinylated 5-HT and the non-biotinylated samples for the fixed number 
of the goat anti-rabbit (GAR) primary antibody as described in the 5-HT ELISA kit 
by the manufacturer. The amount of biotinylated antigen bound to the antibody is 
inversely proportional to the analyte concentration of the sample, thus the more 
biotinylated 5-HT bound to the antibody, the less concentrated the sample. The 
microtiter plate was then covered and incubated for 90 minutes at room 
temperature (18 - 25 °C) using an orbital shaker (500 rotations per minute, (rpm)).  
After 90 minutes, the plate was washed three times with 250 µl wash buffer to 
remove non-specifically bound proteins. After which, 150 µl of freshly prepared 
enzyme conjugate (streptavidin alkaline phosphate) was added to each well. The 
plate was covered and incubated on an orbital shaker (500 rpm) for 60 minutes at 
room temperature (18 – 25 °C) to ensure that the enzyme binds to the secondary 
antibody before adding enzymatic substrate. This was followed by another wash 
step (3 x 250 µl) with the wash buffer.  A 200 µl aliquot of p-nitrophenyl phosphate 
(PNPP) substrate solution was added into each well and incubated for 60 minutes 
at room temperature using an orbital shaker at 500 rpm. This causes a catalytic 
reaction whereby the streptavidin alkaline phosphate acts on the PNPP substrate 
to produce a colour change, corresponding to the protein concentration. The 
substrate reaction was stopped by adding 50 µl of PNPP stop solution (1 M NaOH) 
and shaking the plate to mix the contents in the plate (Appendix C2). After which, 
the absorbance (optical density, OD) levels were read at 405 nm with a 





The 5-HT concentration of the controls and samples was read from the standard 
curve. The 5-HT concentration of the hypothalamic samples was within the 
standard range as specified in the quality control certificate of the kit (0.08 - 19.8 
ng/ml) (Figure 2.7) (Appendix C3).  In contrast, the 5-HT concentration of PFC 
tissue was not within the standard range (0.08 – 19.8 ng/ml) (Figure 2.8) 
(Appendix C4). Specifically, 2 samples (0.058 and 0.022 ng/ml) from the NMS 
CCL group and 3 samples (0.026, 0.057 and 0.033 ng/ml)  from the MS CCL were 
below the lowest standard (0.08 ng/ml) (Figure 2.8). A possible explanation for low 
5-HT concentrations could be that exposure to CCL in both groups (NMS and MS) 
might have reduced the 5-HT concentration below that of the lowest standard. 
Another more plausible explanation for the low values could be as a result of 
dilution factor as the samples were highly diluted (50 mg wet weight: 1 ml RIPA) 
with sample preparation before further dilutions (x107) of the samples during the 



















(Standard curve generated using the free online curve fitting tool for ELISA analysis, readerfit.com) 
Figure 2.7: The standard curve diagram for the 5-HT concentration (ng/ml) in the hypothalamic tissue samples. The 5-HT 













(Standard curve generated using the free online curve fitting tool for ELISA analysis, readerfit.com) 
Figure 2.8: The standard curve for the 5-HT concentration (ng/ml) in the prefrontal cortex (PFC) tissue samples. The 5-HT 
concentration of the tissue samples of the PFC  (indicated by green data points) was not within the range of the standards; as 5 samples, 2 





2.5.2 Western blotting  
On PND 80 rats were killed by decapitation between 09h00 - 12h00.  Following 
decapitation, the whole hypothalamus was dissected and stored in liquid nitrogen 
until analysed. Coronal slices (0.9 mm2) of the brain were cut with a Mcllwain 
tissue chopper as indicated in Figure (2.4). The PFC and NAc core and shell sub-
regions were dissected from the first four brain slices and kept in liquid nitrogen 
until analysis.  








Tissue samples of each NAc core, NAc shell tissue, PFC and hypothalamus were 
weighed (grams) and diluted by a factor of 19 using RIPA buffer (Appendix C1). 
Two µl of protease inhibitor cocktail (Thermo Scientific, Rockford, USA) per 1 ml of 
RIPA buffer was added to the buffer solution to prevent the loss of proteins from 
breakdown by enzymes, proteases. After which the tissue samples were sonicated 
for 10 seconds to assist in protein breakdown and extraction, mixed on a vortex for 
another 10 seconds and left to stand on ice for 20 minutes. 
After 20 minutes, samples were centrifuged at 17200 x g for 30 minutes at 4 °C 
and the supernatant was collected and kept overnight at -20 °C.  The next day, the 
Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, USA) was used to 
determine protein concentration (Appendix D1). This was achieved by diluting 10 
µl of tissue sample with 50 µl RIPA buffer. Two 25 µl (duplicate) aliquots of each 
 Please note that the tissue preparation for Western blot analysis was 
the same for all the proteins (MOR-1, OXR-1 and OXR-2 and orexin 
peptide A and B). However, the characterisation of antibodies used for 
each of these proteins was slightly different.  
 
 See the Appendices for the list of buffers, reagents and additional 









standard and tissue sample were added to the respective wells of the microtiter 
plate. This was followed by an addition of 200 µl working reagent (Appendix D1) to 
each well.  The microtiter plate was covered with parafilm and incubated at 37 °C 
for 30 minutes. After which, the absorbance was recorded at 562 nm using a 
spectrophotometer (Appendix F). 
The absorbance values of the standards were used to generate a standard curve 
against their known concentration in order to determine the protein concentration 
(g/l) of the tissue samples (Appendix D2). From this, different protein samples 
(10 µg, 20 µg and 30 µg protein) were loaded into the wells for the characterisation 
for specific antibodies and Western blot procedures. 
2.5.2.2 Characterisation procedure 
2.5.2.2.1 Electrophoresis 
Characterisation of MOR-1, OXR-1 and OXR-2 as well as orexin A and B protein 
levels began with testing different concentrations of protein (10 µg, 20 µg and 30 
µg) to yield the best optimal results for analysis of protein levels (Figure 2.9). It is 
important to note that the characterisation of the larger molecular weight proteins 
(MOR-1, 50 kDa; OXR-1, 56 kDa and OXR-2, 38 kDa) was performed using a 12 
% separating and 5 % stacking (bis-acrylamide) sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel using Bio-Rad Laboratories 
(USA) apparatus (Appendix D3). This type of gel contains large pores that are 
suitable for the separation of larger molecular weight proteins such as MOR-1, 
OXR-1 and OXR-2. A more concentrated SDS-PAGE gel (18 % separating and 
5% stacking) (smaller pore size) was used for the smaller molecular weight 
peptides (Orexin A, 3.56 kDa and Orexin B, 2.94 kDa)( Appendix D4).   
Each of these protein concentrations (10 µg, 20 µg and 30 µg) were loaded onto 
four gels using a Hamilton syringe which was rinsed well between sample loading. 
Moreover, a larger molecular weight protein marker (M) for the large proteins 
(MOR-1, OXR-1 and OXR-2) and smaller molecular weight protein marker for the 




indicated in Figure 2.9 for estimating the size of the proteins (Appendix D5). Gel 
electrophoresis was performed at 150 – 200 V for 1.17 hours to 2.5 hours in order 





Figure 2.9: An example of the characterisation gel layout. Different amounts of 
sample tissue protein (µg) were loaded on the gel.  The membrane was cut (along the 
dotted line indicating where the protein marker (M) was loaded) into three parts. Each of 
the three parts were incubated with different concentrations (1:5000, 1:6000: 1:7000) of 
the primary antibody.  
 
2.5.2.2.2 Electrotransfer 
After gel electrophoresis, the larger proteins (MOR-1, OXR-1 and OXR-2) were 
transferred into the nitrocellulose membrane (0.45 µm, Hybond ECL, GE Health 
Life Sciences, UK) at 100 V for 1 hour. Orexin A and B protein samples were 
transferred using a nitrocellulose membrane with a small pore size (0.2 µm) since 
a 0.45 µm nitrocellulose membrane increases the risk of losing small protein 
through the larger pores. The nitrocellulose membranes were stained with 
Ponceau S to determine if protein transfer was successful. This was followed by a 
30-minute wash step (3 x 10 minutes) with distilled water to remove the stain 





2.5.2.2.3 Blocking and antibody incubation 
A 5 % bovine serum albumin (BSA) in phosphate buffered saline with 0.1 % 
Tween (PBS-T) solution was used to block the nitrocellulose membrane for 2 
hours at room temperature or overnight at 4 °C in order to reduce background. 
This is achieved by preventing non-specific binding of the primary antibody to the 
membrane, as it contains a large number of proteins. The different blocking times 
were tested in order to determine optimal conditions for analysing the protein band 
of interest. It is important to note that 5% BSA was chosen as the optimal blocking 
buffer solution after the 5 % non-fat milk buffer solution did not produce any 
protein bands on the X-ray film, suggesting that the 5 % non-fat milk buffer 
solution was blocking the signal of the primary antibodies. 
 
 The nitrocellulose membranes were then immunolabelled with rabbit polyclonal 
IgG primary antibody against MOR-1(sc- 7488, Santa Cruz Biotechnology) at 
different dilution ratios (1:200 - 1:7000) for analysing MOR-1 protein levels (Figure 
2.8). A goat polyclonal IgG primary antibody against OXR-1 (sc- 8072, Santa Cruz 
Biotechnology) and OXR-2 (sc- 8074, Santa Cruz Biotechnology) at different 
dilution ratios (1:100 - 1:7000) was used for OXR-1 and OXR-2 protein analysis. It 
is important to note that the different concentrations of the primary antibodies were 
tested starting with the dilution ratio recommended by the manufacturer.  
The incubation periods of tissue samples with the primary antibody also varied 
(1.5 hours at room temperature or overnight at 4 °C) to determine optimal dilution 
of the primary antibodies and incubation time for measuring MOR-1, OXR-1 and 
OXR-2 as well as orexin A and B protein levels. After incubation with the primary 
antibodies, the membranes were washed for 30 minutes (3 X10 minute) in order to 
remove excess unbound antibody and minimize background noise. This was 
followed by incubation with a secondary antibody (Goat-anti Rabbit, conjugated to 
a horseradish peroxidase (HRP) enzyme (GAR, IgG (H+L) - HRP Conjugate, Bio-
Rad #170-6515) for MOR-1 and (Rabbit-anti goat, RAG IgG-HRP Conjugate,sc-
2768, #F2910, Santa Cruz Biotechnology) for OXR-1 and OXR-2 to produce a 
signal corresponding to the position of the target protein. The HRP attached to the 




chemiluminescent agent in the ECL substrate thus producing photo signal as a by-
product (Veitch et al., 2004). Various concentrations (1:5000 - 10000) of GAR 
(MOR) and RAG (OXR-1 and OXR-2) were tested during the characterisation 
stage for optimising MOR-1, OXR-1 and OXR-2 as well as orexin A and B 
measurement. Incubation of the secondary antibody was conducted for 2 hours at 
room temperature.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
2.5.2.2.4 Detection  
After incubation with the secondary antibody, excess antibody was removed by 
washing the nitrocellulose membranes for 30 minutes (3 X10 minute) with PBS-T.  
After which, 1500 µl Clarity Western ECL Substrate (Bio-Rad Laboratories Inc. 
USA) consisting of reagent A (750 µl, clarity Western peroxide reagent) and 
reagent B (750 µl, luminol/enhancer reagent) was applied to the nitrocellulose 
membranes. The membranes were exposed to the ECL substrate for 1 minute by 
swirling the clear transparencies containing the membranes. Excess ECL 
substrate solution was removed. The HRP-conjugate bound to the secondary 
antibody catalyses the luminal substrate (B) in the presence of substrate A 
(peroxide) thereby producing a luminescence signal. The luminescence was 
captured by exposing the membranes to X-ray film.  Exposure time to the X-ray 
film was also optimised. 
 
2.5.2.2.5 Quantification using UN-SCAN IT 
All the X-ray films were scanned at 600 dpi and saved in a tag image file format 
(TIFF). The images were then analysed using the positive segment analysis of the 
UN-SCAN-IT software (Silk Scientific Inc. Utah, USA). The blot images were 
converted to a grey scale and a background segment was selected to correct for 
background pixilation. Bands of interest were selected and pixel density of each 
protein band was determined (minus background pixel density). The pixel total in 
each segment and pixel total percentage data was generated by the UN-SCAN-IT 




protein levels were calculated by dividing the total number of pixels of each protein 
band by the sum of the pixel totals of all bands in that segment in order to obtain 
the pixel total of each protein band as a percentage of the pixel total of all the 
samples on the membrane. 
 
 2.5.2.2.6 Optimal conditions for MOR-1, OXR-1 and OXR-2 protein levels 
Based on the characterisation work, the best conditions for analysing MOR-1 in 
the NAc, OXR-1 and OXR-2 protein levels in the PFC are indicated in Table 2.1. A 
linear curve was generated for determining the optimal protein concentration for 
each primary antibody and for detecting differences in protein levels between the 
experimental groups (Figure 2.10).  A protein aliquot of 20 µg for MOR-1 and 
OXR-2 and 24 µg for OXR-1 were chosen using the standard curves shown in 
Figure 2.9. Protein samples were loaded as indicated in Figure 2.11; different 
samples (n=8) from the four experimental groups; NMS rats, NMS rats exposed to 
CCL, MS and MS rats subjected to CCL were loaded as indicated in Figure 2.11. 
Samples that were not easily quantified due to technical artefacts were repeated. 
The rest of the Western blot assay analysis was carried out as stated in the 







Figure 2.10: Optimal protein concentration graphs. Linear curve graphs used to optimise the amount of protein applied to the gel for 























Figure 2.11:  An example of a gel layout used for loading protein samples (n=8) in the gel. Two different protein samples from each 
experimental group: non-maternal separated (NMS) rats, NMS rats exposed to CCL, maternal separated (MS) animals and MS rats 





Table 2.1: Optimal conditions for measurement of  MOR-1 in the NAc, OXR-1 and OXR-2 in the PFC protein levels 
 
Abbreviations: µ-opioid receptor (MOR-1), Bovine serum albumin (BSA), Goat anti-rabbit (GAR), Kilo Dalton (KDa), Molecular weight 
protein marker (M), orexin receptor 1 and 2 (OXR-1 and OXR-2), Rabbit anti-goat (RAG), Volts (V) 




Table 2.2: Different conditions used to characterise Western blot analysis of 
orexin A and B peptides in the hypothalamus 
 
Abbreviations: Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
Polyvinylidene difluoride (PVDF), Volts (V) 
 
Characterisation of orexin A and B peptides was unsuccessful with tissue samples of 
10 µg, 20 µg and 30 µg proteins. There were no protein bands visible below 
the15kDa molecular weight protein marker as shown in Figure 2.12. It was therefore 
proposed that the amount of orexin A and B protein in the tissue samples was too 
low to be detected using Western blot analysis. To test this hypothesis, the amount 
of protein applied to the gel was increased to 70 µg, 80 µg and 90 µg, despite this 
there were still no protein bands present with the molecular weight size of orexin A 
(3.56 kDa) or Orexin B (2.94 kDa) peptides.  
 It was also hypothesised that the small peptides might be running off the gel before 
electrophoresis was completed. Therefore, instead of performing the gel 
electrophoresis for 1.5 hours, of which was chosen in order to get a clear separation 
of the protein samples, a shorter electrophoresis time (30 minutes) was tested to 
determine if this would minimise the loss of small proteins. However, there were still 
no proteins present between 15 kDa to 1.7 kDa (Figure 2.12). Several attempts were 
made to optimise the procedure, such as altering the transfer conditions as shown in 
Table 2.2. For example, high voltage (e.g. 100 V) vs. a low voltage (e.g. 60 V) was 




proteins to the membrane.  Both 100 V and 60 V did not yield any differences, even 
transferring for different periods of time (1 hour vs. 30 minutes) did not produce any 
protein bands on the membranes.  Similarly, no protein bands were visible when 
either nitrocellulose or PDVF membrane were used, suggesting that the problem 
might be due to the small molecular weights of the peptides, A (3.56 kDa) and 
Orexin B (2.94 kDa).  This also suggested that the western blot might not have been 
sensitive enough to detect these peptides, despite several studies using the same 
technique to analyse orexin A and B protein levels in the hypothalamus and NAc 
(Karteris et al., 2005; Zhang et al., 2007). For future studies, more sensitive 
techniques such as the radioimmunoassay or ELISA assay techniques should be 






Figure 2.12: Characterisation of orexin peptides. An example a nitrocellulose 
membrane (0.2 µm) with different amounts of protein samples (10 µg, 20 µg and 30 
µg) for orexin A peptide. There were no protein bands visible around the 4.6 KDa 
molecular weight protein marker to indicate the presence of orexin A (3.56 KDa). 
 
 2.5.2.2.7 Housekeeping proteins 
The same blots used during the characterisation procedure of the MOR-1, OXR-1 




antibody produced in mouse (MOR-1) (#T5168, Sigma-Aldrich, Missouri, USA) and 
anti-p38 MAP Kinase antibody produce in rabbit (OXR-1 and OXR-2) (#M0800, 
Sigma-Aldrich, Missouri, USA).  Both α anti-tubulin and anti-p38 were used as 
loading controls to confirm that samples were evenly loaded in the gel, as this is 
important for comparing protein levels between the experimental groups. 
Characterisation of the α-tubulin antibody was achieved by washing the blots with 
distilled water for 20 minutes (2 x10 minutes) and followed by a 5-minute exposure to 
0.2 M NaOH solution to strip primary and secondary antibodies from the blots 
(Appendix D6).  After the 5-minute stripping period, the blots were washed again with 
distilled water (2 x 10 minutes). The blots were then blocked with 5 % non-fat milk in 
PBS-T for 2 hours at room temperature. The remaining steps of the Western blot 
assay were performed in the same way as described in the characterisation 
procedure section except that goat anti-mouse (GAM, IgG (H+L) - HRP Conjugate, 
Bio-Rad #172-1011) secondary antibody was used during the incubation step. 
 
Table 2.3: Optimal conditions for primary and secondary antibodies used to 
measure α- tubulin and p38 in the different gels  
 
Abbreviations: µ-opioid receptor (MOR-1), orexin receptor 1 and 2 (OXR-1 and OXR-2), 
goat anti mouse (GAM), goat anti rabbit (GAR) 
2.6 Statistical Analysis 
Data analysis was performed using Statistica version 11 (Statsoftinc, Tulsa, 
Oklahoma, USA) and graphs were designed using the GraphPad Prism version 6 




Shapiro-Wilk test was used to determine if the data were normally distributed. 
Glutamate- and potassium-stimulated [3H]DA release data, 5-HT levels  and MOR-1 
levels data were all normally distributed. Similarly, the pixel total percentages of 
OXR-1 and OXR-2 levels data were normally distributed. However, 5-HT levels in 
the PFC were not normally distributed. Similarly, when the OXR-1 protein from each 
sample was normalised against the housekeeping protein (p38), the data were not 
normally distributed. Furthermore, p38 protein levels (for OXR-1) were also not 
normally distributed. 
 
For all the normally distributed data, a parametric analysis was conducted using a 
two-way analysis of variance (ANOVA) to determine statistical significance of the 
effects of MS and CCL on the experimental groups; non-maternally separated (NMS) 
rats, NMS rats subjected to CCL (NMS CCL), MS rats and MS rats subjected to CCL 
(MS CCL). Two-way ANOVA was followed by Duncan’s post hoc test. All the data 
are presented as mean and standard error mean (SEM). 
 
On the other hand, non-parametric data were analysed using the Kruskal-Wallis test 
to determine statistically significant differences in 5-HT levels in the PFC between 
the experimental groups.  Where appropriate, significant Kruskal-Wallis tests were 







CHAPTER 3: RESULTS 
 
3.1 Glutamate- and potassium-stimulated [3H]DA release in the NAc 
core 
Two-way ANOVA of glutamate-stimulated [3H]DA release revealed that there was no 
significant effect of MS (F(1,49) =1.564, p=0.217) or CCL (F(1,49) =0.704, p=0.406) in 
the NAc core (Figure 3.1). There was no interaction between the main effects of MS 
and CCL (MS*CCL; F(1,49) =1.558, p=0.218) on glutamate-stimulated [3H]DA release 
in the NAc core. 
 Two-way ANOVA of potassium-stimulated [3H]DA release did not show any 
significant effect of MS (F(1,43)=0.659, p=0.421) or CCL (F(1,43)=0.107, p=0.746) in the 
NAc core ( Figure 3.2). There was also no interaction between MS and CCL 
(MS*CCL; F(1,43) =1.321, p=0.257) on potassium-stimulated [3H]DA release in the 




Figure 3.1: Column (A) and scatter plot (B) graphs showing glutamate-stimulated 
[3H]DA release measured in the NAc core at P80 using in vitro superfusion. Two-way 
ANOVA showed no significant differences in glutamate-stimulated [3H]DA release between 
the groups; non-maternally separated animals (NMS, n=13); non-maternally separated 
animals subjected to chronic constant light (NMS CCL, n=11); maternally separated animals 
(MS, n=14) and maternally separated animals exposed to chronic constant light (MS CCL, 
n=13). Data presented as mean ± SEM. 
 
Figure 3.2: Column (A) and scatter plot (B) graphs for potassium-stimulated [3H]DA 
release in the NAc core at P80. Two-way ANOVA indicated no significant differences in 
potassium-stimulated [3H]DA release between experimental groups; non-maternally 
separated animals (NMS, n=11), non-maternally separated animals exposed to chronic 
constant light (NMS CCL, n=10), maternally separated (MS, n=12) and maternally separated 




3.2 Glutamate- and potassium-stimulated [3H]DA release in the NAc 
shell 
 
Two-way ANOVA of glutamate-stimulated [3H]DA release did not reveal any MS 
effect in the NAc shell (F(1,46) =2.346, p=0.133). There was no interaction between 
MS and CCL (MS*CCL; F(1,46) =0.185, p=0.669) on glutamate-stimulated [3H]DA 
release in the NAc shell. On the other hand, a decreased trend towards significance 
was observed for CCL exposure (F(1,46) =2.990, p=0.091) on glutamate-stimulated 
[3H]DA release in the NAc shell (Figure 3.3). 
 
There was also no MS effect found on potassium-stimulated [3H]DA release in the 
NAc shell (Two-way ANOVA, F(1,38)=1.735, p=0.196). However, a trend towards a 
significant decrease was revealed in potassium-stimulated [3H]DA release after CCL 
exposure (F(1,38) =3.604, p=0.066)  (Figure 3.4). There was also no interaction 
between the MS and CCL effects on potassium-stimulated [3H]DA release in the NAc 
shell (F(1,38)=0.642, p=0.428). 
 
 
Figure 3.3: Column (A) and scatter plot (B) graphs for glutamate-stimulated [3H]DA 
release in the NAc shell at P80. No significant differences were observed in glutamate 
stimulated [3H]DA release between the groups; non maternally separated animals (NMS, 
n=11); non-maternally separated  animals subjected to chronic constant light (NMS CCL, 




to chronic constant light (MS CCL, n=14) (Two-way ANOVA). Data presented as mean ± 
SEM. 
Figure 3.4: Column (A) and scatter plot (B) graphs for potassium-stimulated [3H]DA 
release in the NAc shell at P80. Two-way ANOVA revealed that there are no significant 
differences in [3H]DA release after potassium stimulation between the experimental groups; 
non-maternally separated (NMS, n=10), non-maternally separated animals exposed to 
chronic constant light (NMS CCL, n=9), maternally separated (MS, n=10) and maternally 
separated animals exposed to chronic constant light (MS CCL, n=11). Data presented as 
mean ± SEM.  
3.3 Glutamate- and potassium-stimulated [3H]DA release in the NAc 
The NAc core and shell data were pooled and the average for each rat used as a 
representative measure of the function of the NAc as a whole. It is important to note 
that rats in which only the core or shell data points were obtained, the single core or 
shell data point was included in the analysis. A decreased glutamate-stimulated 
[3H]DA release in the NAc was found after MS exposure (Two-way ANOVA, F(1,51) 
=4.934, p=0.031). On the other hand, there was no main effect of CCL on glutamate-
stimulated [3H]DA release, however a decreased trend was observed (Two-way 
ANOVA, F(1,51)=2.863, p=0.097) (Figure 3.5). There was no interaction between MS 
and CCL (MS*CCL; F(1,51) =0.518, p=0.475) on glutamate-stimulated [3H]DA release 





There was neither MS effect (Two-way ANOVA, F(1,43)= 1.146, p=0.291) or CCL 
effect (Two-way ANOVA, F(1,43)= 0.068, p=0.795) on potassium-stimulated [3H]DA 
release in the NAc (Figure 3.6). There was no interaction between MS and CCL 




Figure 3.5: Column (A) and scatter plot (B) graphs showing glutamate-stimulated 
[3H]DA release in the NAc as a whole at P80.  Two-way ANOVA indicated a significant 
effect of MS on glutamate-stimulated [3H]DA release in the NAC between the experimental 
groups; non-maternally separated (NMS, n=13); non-maternally separated animals 
subjected to chronic constant light (NMS CCL, n=12); maternally separated (MS, n=14) and 
maternally separated animals exposed with chronic constant light (MS CCL, n=14).  
 
Figure 3.6: Column (A) and scatter plot (B) graphs showing potassium-stimulated 
[3H]DA release in the NAc as a whole at P80. Two-way ANOVA revealed no significant 
differences in potassium-stimulated [3H]DA release between the groups; non-maternally 
separated animals (NMS, n=11); non-maternally separated animals exposed to chronic 




separated animals exposed to chronic constant light (MS CCL, n=12).  Data expressed as 
mean ± SEM. 
3.4 Serotonin concentration in the hypothalamus  
MS did not reveal any significant effect on 5-HT levels in the hypothalamus (Two-
way ANOVA, F(1,37)=2.431, p=0.128). There was also no interaction between MS and 
CCL (MS*CCL; F(1,37) =1.011, p=0.322) on 5-HT levels in the hypothalamus. On the 
contrary, 5-HT levels were significantly increased in both NMS and MS rats 
subjected to CCL compared to NMS and MS rats without CCL exposure (Two-way 
ANOVA, F(1,37)=11.810, p=0.002) (Figure 3.7).  
 
 
Figure 3.7: Column (A) and scatter plot (B) graphs showing 5-HT concentration 
(ng/mg) in the hypothalamus at P80. Two-way ANOVA revealed significant effect 
of CCL on 5-HT in the hypothalamus between the experimental groups; non-
maternally separated animals (NMS, n=9); non-maternally separated animals 
subjected to chronic constant light (NMS CCL, n=10); maternally separated animals 
(MS, n=10) and maternally separated animals exposed to chronic constant light (MS 





3.5 Serotonin concentration in the PFC 
The Kruskal-Wallis test (H(3, 35)=20.744, p<0.001) followed by Dunn’s multiple 
comparison test showed that NMS CCL rats had significantly decreased 5-HT levels 
when compared to NMS (p=0.003). In addition, MS CCL rats had reduced 5-HT 
levels in comparison to NMS rats (p< 0.001) (Figure 3.8). Furthermore, MS CCL rats 
had reduced 5-HT concentration when compared to MS, however this did not reach 
a statistical significance (p=0.058). 
  
Figure 3.8: Column (A) and scatter plot (B) graphs for 5-HT concentration (ng/mg) 
measured in the PFC at P80. Kruskal-Wallis test showed significant differences in 5-HT 
between the experimental groups; non-maternally separated animals (NMS, n=10); non-
maternally separated animals exposed to chronic constant light (NMS CCL, n=9); maternally 
separated animals (MS, n=10) and maternally separated animals exposed to chronic 
constant light (MS CCL, n=10). *NMS CCL rats had decreased 5-HT compared to NMS rats, 
p< 0.05.  #MS CCL rats had significantly decreased 5-HT compared to NMS, p<0.001 
(Dunn’s multiple comparison test).  Data expressed as median and IQR. 
3.6 MOR-1 protein levels in the NAc core 
Neither MS (Two-way ANOVA, F(1,35) =0.453, p=0.505) nor CCL (Two-way ANOVA, 
F(1,35)=0.931, p=0.341) had an effect on MOR-1 protein levels in the NAc core 
(Figure 3.9). There was no interaction between MS and CCL (MS*CCL; F(1,35) 
=2.245, p=0.143) on MOR-1 protein levels in the NAc core. Two-way ANOVA of 




p=0.491) nor a CCL (F(1,35)=0.168, p=0.685) effect on MOR-1 protein levels in the 
NAc core (Appendix H4). There was no interaction between MS and CCL (MS*CCL; 
F(1,35) =1.171, p=0.287) on normalised MOR-1 protein levels in the NAc core. 
Two-way ANOVA of α-tubulin protein levels revealed no significant effect of MS 
(F(1,35)=0.069, p=0.794)  or CCL  (F(1,35)=1.045, p=0.314) or interaction between MS 
and CCL (MS*CCL; F(1,35) =0.552, p=0.462) for α-tubulin protein levels, suggesting 
that samples were loaded equally (Appendix H4). 
 
Figure 3.9: Column (A) and scatter plot (B) graphs showing µ-opioid receptor (MOR-1) 
protein levels as measured by western blot analysis of the NAc core. No significant 
differences were found between the groups:  non-maternally separated animals (NMS, 
n=10); maternally separated animals exposed to chronic constant light (NMS CCL, n=9), 
maternally separated animals (MS, n=9) and maternally separated animals exposed to 





3.7 MOR-1 protein levels in the NAc shell 
There was no effect MS (Two-way ANOVA, F(1,32) =0.132, p=0.719)  or CCL 
exposure (Two-way ANOVA, F(1,32)=0.057, p=0.813) on MOR-1 levels in the NAc 
shell (Figure 3.10). There was no interaction between MS and CCL (MS*CCL; F(1,32) 
=1.252, p=0.272) on MOR-1 protein levels in the NAc shell. 
 
Two-way ANOVA of MOR-1 protein levels did not reveal any MS (F(1,32)=0.132, 
p=0.719) or CCL (F(1,32)=0.057, p=0.813) effects on MOR-1 proteins levels in the 
NAc shell when normalised against α-tubulin (Appendix H5). There was also no 
interaction between MS and CCL (MS*CCL; F(1,32) =1.263, p=0.269) when MOR-1 
protein levels were normalised in the NAc shell. 
 
Furthermore, two-way ANOVA of α-tubulin protein levels revealed no significant 
effect in either MS (F(1,32)=0.363, p=0.552) or CCL (F(1,32)=1.824, p=0.187) exposure 
on α-tubulin protein levels, thus indicating equal loading of samples (Appendix H5). 
There was no interaction between the main effects of MS and CCL (MS*CCL; F(1,32) 




Figure 3.10: Column (A) and scatter plot (B) graphs of µ-opioid receptor (MOR-1) 
protein levels measured by western blot analysis of the NAc shell. No significant 
differences were found between the groups: non-maternally separated animals (NMS, n=9); 
non-maternally separated animals exposed to chronic constant light (NMS CCL, n=7), 
maternally separated animals (MS, n=10) and maternally separated animals exposed to 
chronic constant light (MS CCL, n=8) (Two-way ANOVA). Data represented as mean ± 
SEM. 
3.8 MOR-1 protein levels in the NAc 
The MOR-1 protein levels in the NAc shell and core were averaged and pooled to 
obtain a representative measure of the function of the NAc as a whole.  In cases 
where either the shell or core data were not available, only the shell or core result 
was used for statistical analysis. There was also no significant effect of either MS 
(Two-way ANOVA, F(1,43) =1.530, p=0.223) or CCL (Two-way ANOVA, F(1,43)=0.013, 
p=0.909) on MOR-1 levels in the NAc (Figure 3.11). There was no interaction 
between MS and CCL (MS*CCL; F(1,43) =1.288, p=0.2629) on MOR-1 protein levels 





Figure 3.11: Column (A) and scatter plot (B) graphs showing µ-opioid receptor (MOR-
1) protein levels measured by western blot analysis of the NAc. No significant 
differences were found between the groups:  non-maternally separated animals (NMS, 
n=13); non-maternally separated animals treated with chronic constant subjected to chronic 
constant light (MS CCL, n=11), maternally separated rats (MS, n=10) and maternally 
separated rats subjected to chronic constant light (MS CCL, n=11) (Two-way ANOVA). Data 
represented as mean ± SEM. 
3.9 OXR-1 protein levels in the PFC 
Two-way ANOVA of OXR-1 protein levels revealed a significant interaction between 
MS and CCL on OXR-1 protein levels (F(1,36) = 8.303, p=0.007), whereby CCL had 
an opposing effect in NMS and MS rats. Duncan’s post hoc test revealed that MS 
rats had significantly increased OXR-1 protein levels when compared to NMS rats 
(p=0.032) and MS CCL rats (p=0.035) (Figure 3.12). Similarly, when the OXR-1 
protein from each sample was normalised against the housekeeping protein (p38), 
the data were not normally distributed and the Kruskal-Wallis test (H(3, 34)=10.090, 
p=0.018) revealed that there was a significant difference in OXR-1 protein levels 
between groups. Dunn’s multiple comparison test revealed that MS rats had 
significantly increased OXR-1 protein levels when compared to NMS rats (p=0.020) 
(Appendix H6). Furthermore, there were no significant differences in p38 protein 
levels between the experimental groups, thus indicating equal loading of samples, 





Figure 3.12: Column (A) and scatter plot (B) graphs showing orexin receptor 1 
(OXR-1) protein levels as measured by western blot analysis of the PFC. CCL had an 
opposite effect in NMS and MS rats as indicated by the significant interaction between MS 
and CCL in OXR-1 protein levels between the experimental groups; non- maternally 
separated animals (NMS, n=11); non-maternally separated animals subjected to chronic 
constant light (NMS CCL, n=9), maternally separated animals MS (n=9) and MS CCL 
(n=9) (Two-way ANOVA). *MS rats showed a significant increase in OXR-1 protein levels 
compared to NMS rats (p=0.032) and MS CCL rats (p=0.035), Duncan’s post hoc test. 
Data are represented as mean ± SEM. 
3.10 OXR-2 protein levels in the PFC 
There was no effect MS (Two-way ANOVA, F(1,37) =0.906, p=0.348)  or CCL 
exposure (Two-way ANOVA, F(1,37)=0.412, p=0.525) on OXR-2  levels in the PFC 
when only the pixel total (%) was analysed (Figure 3.13.1). However, a trend 
towards a significance between MS and CCL (MS*CCL; F(1,37) =3.791, p=0.059) 
was found in OXR-2 protein levels. When the OXR-2 protein levels were 
normalised an interaction between MS and CCL (MS*CCL; F(1,37) =9.391, p=0.004) 
was revealed. Whereby, CCL had an opposing effect in NMS and MS rats, in 
which OXR-2 protein levels in NMS rats were increased by CCL exposure and the 
opposite was found in MS rats. Duncan’s post hoc analysis revealed that MS rats 




rats (p=0.043) (Appendix H7). Moreover, NMS CCL rats had increased OXR-2 
protein levels when compared to NMS rats; however this did not reach statistical 
significance (p=0.051).  
Furthermore, two-way ANOVA of p38 protein levels revealed no significant effect 
in either MS (F(1,37)=0.056, p=0.815) or CCL (F(1,37)=1.436, p=0.239) exposure, 
thus indicating equal loading of samples (Appendix H7). There was also no 
interaction between MS and CCL (MS*CCL; F(1,37) =1.308, p=0.260) on p38 
protein levels. 
 
Figure 3.13.1: Column (A) and scatter plot (B) graphs of orexin receptor 2 (OXR-2) 
protein levels as measured by western blot analysis of the PFC.  Two-way ANOVA 
did not show any significant differences in OXR-2 levels when only the pixel total % was 
analysed  between the experimental groups; non-maternally separated animals NMS 
(n=11); non-maternally separated animals treated with chronic constant light (NMS CCL, 
n=9), maternally separated animals (MS, n=10) and maternally separated animals 





Figure 3.13.2: Column (A) and scatter plot (B) graphs of normalised orexin receptor 
2 (OXR-2) protein levels as measured by western blot analysis in the PFC.  CCL had 
an opposite effect in NMS and MS rats as indicated by the significant interaction between 
MS and CCL in OXR-2 protein levels between the experimental groups; non- maternally 
separated animals (NMS, n=11); non-maternally separated animals subjected to chronic 
constant light (NMS CCL, n=9), maternally separated animals MS (n=10) and MS CCL 
(n=9) (Two-way ANOVA). *MS rats showed a significant increase in OXR-2 protein levels 
compared to NMS rats (p=0.010) and MS CCL rats (p=0.043), Duncan’s post hoc test. 









CHAPTER 4: DISCUSSION 
4.1 CCL exacerbates the reduction of [3H]DA release in the NAc of MS 
rats 
In this study it was found that neither MS or CCL had any effect on glutamate-and 
potassium-stimulated [3H]DA release in the NAc core. However, in the NAc shell, 
CCL in combination with either NMS or MS resulted in a trend towards a decrease 
in [3H]DA release in response to both glutamate- and potassium-stimulation. When 
the NAc core and shell data were pooled and the average for each rat was used 
as a measure of the function of the NAc as a whole, there was a significant MS 
effect. Rats subjected to MS displayed an overall decrease in glutamate-
stimulated [3H]DA release in the NAc compared to the NMS rats. 
In accordance with these findings, several other rat studies have also reported 
reduced DA activity in the NAc using different stress paradigms such as the FST 
and unavoidable electrical shock (Gambarana et al., 1999; Scheggi et al., 2002). 
For example, decreased levels of extracellular DA in the NAc shell were 
associated with decreased escape latencies in a shock-escape paradigm (Scheggi 
et al., 2002).  Similarly, Gambarana et al. (1999) conducted a study in which rats 
were subjected to acute restraint stress and subsequently electric shocks (I mA x 
5s) as part of a pretest. For the second part of the study, the same rats that were 
exposed to pretest and test trials were tested (48 hours later) again in a chronic 
stress model. Chronic stress exposure caused a significant decrease in DA levels 
in the NAc shell in stressed rats compared to control rats. These findings and 
those reported in the current study indicate that additional stressors (i.e. CCL) 
have a significant reduction in DA release in the NAc.  
Furthermore, Gambarana et al. (1999) administered cocaine and d-amphetamine 
in stressed and control rats to determine if the decreased DA levels were due to 
either reduced function of the dopaminergic neurons or enhanced removal from 
the synaptic cleft by the DA transporters. It was found that DA output was lower in 




other hand, there was no difference in DA output after d-amphetamine between 
the groups. This led to the authors to suggest that reduced function in 
dopaminergic neurons might be a possible mechanism underlying the reduced DA 
levels in stressed rats (Gambarana et al., 1999). Thus it is possible that exposure 
to MS and CCL might have reduced dopaminergic neurons function causing a 
reduction of [3H]DA release in the nucleus accumbens, future studies are required 
to validate this notion. 
In contrast to the altered DA levels following stress, Jahng et al. (2010) did not 
report any significant differences in accumbal DA levels of rats subjected to MS 
and subsequent restraint stress (1 h) compared to control animals. It was 
proposed that the lack of significant decrease in DA levels following restraint 
stress was due to long-term effects of MS that might have suppressed the effect of 
subsequent restraint stress on DA activity in the NAc. Thus the suppressed DA 
function might have impaired the ability of the DA system to respond to stressful 
stimuli later in life. This study suggests that although MS alone is not a robust 
model, it does have a long-term effect on DA function. Further evidence comes 
from findings reported in the current study; MS alone was not sufficient to cause a 
significant reduction in [3H]DA release. However, when MS and CCL were 
combined glutamate- and potassium-stimulated [3H]DA release showed a trend 
towards a decrease in the NAc shell, suggesting that MS might have suppressed  
DA activity thereby causing a further reduction in [3H]DA release  as a result of 
exposure to CCL. Therefore, these results provide evidence for the combined 
effects of MS and CCL in altering DA activity and most importantly as a robust 
model to study biological systems implicated in depression. 
The NAc shell appeared to be more sensitive to the effects of MS and CCL than 
the NAc core, as there was a tendency for CCL to decrease the release of 
glutamate- and potassium-stimulated [3H]DA release in the NAc shell.  No 
significant change was noted in the NAc core. A possible explanation for the 
sensitivity of the shell to the combined effects of MS and CCL might be due to its 
anatomical connections. The shell is mostly connected to limbic nuclei in the brain 
whereas the core is mostly connected to the motor nuclei (Heimer et al., 1991). 




important subregion mediating certain DA functions (Heimer et al., 1991). 
Therefore, the shell is more involved in regulating mood behaviours, hence the 
altered responsivity of the NAc shell to the effects of MS and CCL compared to the 
core subregion.  
Another plausible explanation is that the combination of MS and CCL might have 
altered glutamate receptor sensitivity thus reducing [3H]DA release in the NAc. For 
example, Hu et al.(1999) using in vivo microdialysis showed that group two 
metabotropic glutamate receptor (mGLuR2/3) agonist reduces extracellular 
glutamate in the NAc. This means that reduced extracellular glutamate due to 
enhanced mGLuR2/3 would reduce DA levels in the NAc. Similarly, Xi et al. (2002) 
found that mGLuR2/3 immunoproteins were highly expressed in the shell and core 
subregions of the NAc. Moreover, it was reported that mGLuR2/3 agonist caused 
a dose-dependent decrease in extracellular glutamate levels in the NAc and this 
effect was reversed by administration of a mGLuR2/3 antagonist (Xi et al., 2002). 
Also in agreement with these findings, Karasawa et al. (2006) showed that 
injection of a selective mGLu 2/3 receptor agonist decreased DA levels in the NAc 
shell whereas an mGLu 2/3 receptor antagonist had opposing effects on DA. 
Furthermore, increased DA levels induced by an mGLuR2/3 receptor antagonist 
were shown to induce antidepressant-like behaviour in rats (Chaki et al., 2004).  
Therefore, the decreased glutamate-stimulated [3H]DA release found in the NAc of 
MS CCL rats suggests that the effects of MS and CCL might have increased 
mGLu 2/3 receptor sensitivity in the NAc. This may in turn have reduced the 
extracellular glutamate levels leading to a subsequent decrease in [3H]DA release. 
Future studies are required to validate these claims.  
The interaction of DA and serotonin at the accumbal level could also be an 
explanation for the decreased glutamate-stimulated [3H]DA release. Serotonin 
modulates DA release in the NAc and PFC (Yoshimoto et al., 1996; Hallbus et al., 
1997; Di Matteo et al., 2001). Serotonin-induced DA release in the NAc is believed 
to be mediated through the activation of 5-HT receptors such as 5-HT1A, 5-HT3 
and 5-HT2A in the NAc (Campbell and McBride, 1995; Ichikawa and Meltzer, 2000; 
Lucas and Spampinato, 2000). The excitatory-life effects of 5-HT1A, 5-HT3 and 5-




HT2c receptors that activate GABA neurons that project to the DRN causing a 
reduction in 5-HT firing cells (Tao and Auerbach, 2000; Di Matteo et al., 2001). 
Therefore, an imbalance between the excitatory and inhibitory 5-HT receptors 
might alter DA release in the NAc. As a result, it is also possible that MS and CCL 
might have altered the activity of 5-HT1A, 5-HT3 and 5-HT2A receptors by 
desensitizing them and causing a reduction in 5-HT levels. This would in turn 
induce a decrease in [3H]DA release in the NAc. It is also possible that the effects 
of CCL and MS might have increased the number of 5-HT2C receptors causing 
more inhibitory activity in the NAc. As a result, the inhibitory effects of 5-HT2CR 
would decrease 5-HT levels and reduce glutamate-stimulated [3H]DA release in 
the NAc.  
Further evidence of the 5-HT-induced DA activity in the NAc originates from the 
use of antidepressant (SSRIs) which increase extracellular levels of 5-HT by 
blocking its re-uptake into the presynaptic cell (McEwen et al., 1993; Deana et al., 
2001). Serotonergic neurons within the NAc are essential for regulating 
dopaminergic functions; motivation, reward and various forms of stress and it is 
believed that these functions are mediated by the antidepressant effects of SSRIs 
(McEwen et al., 1993; Deanna et al., 2001). Moreover, the fast onset 
antidepressants act through various 5-HT receptors thereby regulating DA release 
in the NAc (Parsons and Justice, 1993; Campbell and McBride, 1995; Ichikawa 
and Meltzer, 1999; Lucas and Spampinato, 2000; Di Matteo et al., 2001). For 
example, reduced extracellular DA levels in FSL rats were elevated after 
administration of nefazondine, a potent 5-HT2C antagonist (Sanchez et al., 1999; 
Dremencov et al., 2004; Wesolowska et al., 2006). The 5-HT2C receptor antagonist 
induces an immediate increase in DA levels in the NAc of FSL rats (Dremencov et 
al., 2005). Moreover, the ability of 5-HT to induce DA release was also correlated 
with improvements of depressive-like behaviour in FSL rats (Dremencov et al., 




4.2 Serotonin levels in the hypothalamus and PFC are altered by the 
effects of MS and CCL 
In addition to altered [3H]DA release in the NAc by MS and CCL it was further 
demonstrated that 5-HT levels in the hypothalamus and PFC were also altered by 
MS and CCL. In the hypothalamus, CCL exposure caused an overall increase in 
5-HT levels whereby both NMS and MS rats displayed a significant increase in 5-
HT levels than NMS and MS rats without CCL exposure. Despite not showing a 
statistical difference, the MS rats subjected to CCL exposure showed augmented 
5-HT levels in the hypothalamus and this increase was greater than the increased 
5-HT levels of NMS rats subjected to CCL, suggesting that the combination of MS 
and CCL is a greater stressor and hence has a greater effect in altering 5-HT 
levels than when MS or CCL is used as the sole stressor. On the other hand, in 
the PFC, NMS and MS rats exposed to CCL exhibited reduced 5-HT levels in 
comparison to NMS rats. Similarly, addition of CCL further reduced 5-HT levels in 
the PFC of MS rats compared to MS alone, as the sole stressor. Therefore, 
addition of CCL exaggerates the effects of MS causing alterations in 5HT levels in 
the hypothalamus and PFC. 
The 5HT-ergic response to different stressors varies, as demonstrated by the fact 
that stress increases or decreases or has no effect on extracellular levels of 5-HT 
in different brain areas such as the PFC, hippocampus and amygdala (Kirby et al., 
1995; Kirby and Lucki, 1997).  Moreover, the reactivity of the 5HT-ergic system is 
inconsistent and varies with the type of stressor or brain area (Keeney et al., 
2006). This might explain the disparate 5-HT levels found in the hypothalamus and 
PFC, further providing evidence of the reactivity of the 5HT-ergic system in 
different brain regions.  
Altered 5-HT levels in the rat brain have been reported in other animal models of 
depression and other stress paradigms (Zangen et al., 1997; Rentesi et al., 2010). 
In a genetic rat model of depression, FSL, 5-HT and its metabolites (5-HIAA) were 
significantly higher in the hypothalamus, NAc and PFC compared to control rats 




correlated with high immobility in the FST, which is indicative of depressive-like 
behaviours.   
Furthermore, different forms of stress (swimming, cat exposure, tail pinch) 
increased 5-HT levels (20-65%) above baseline levels in the PFC (Rueter and 
Jacobs, 1996). Increased 5-HT levels in the hypothalamus and increased anxiety-
like behaviour in the OFT were also reported after MS (Rentesi et al., 2010).  
Moreover, MS rats displayed elevated ACTH and CORT levels consistent with the 
stressful effects of MS (Rentesi et al., 2010). On the other hand, decreased 5-HT 
levels were reported in the hippocampus, PFC and amygdala of rats subjected to 
MS compared to NMS rats (Matthew et al., 2001; Lee et al., 2007). The 
discrepancies might be due to duration of the MS paradigm, whereby MS rats in 
the study conducted by Rentesi et al. (2010) were separated for 24 hours from the 
dams for PND 9. This is in contrast to the 3 and 6 hour daily MS procedure 
performed by Matthew et al. (2001) and Lee et al. (2007) over a two week period.  
These studies further indicate that the 5HT-ergic system is highly susceptible to 
various forms of stressors, further providing evidence of the effects of MS and 
CCL exposure in altering 5-HT levels in the hypothalamus and PFC. Reduced 5-
HT levels attenuate the stress response whereas increased 5-HT levels assist 
animals in responding to stress (Mo et al., 2008). According to Mo et al. (2008) 
restraint stress increases 5-HT levels in the amygdala by activating CRF which is 
secreted by the PVN of the hypothalamus in response to stress. Therefore, it is 
plausible that the elevated 5HT-levels in the hypothalamus of MS and CCL 
exposed animals might have activated CRF secretion in order to cope with the 
effects of the combined stress of MS and CCL.  
The altered 5-HT levels in the hypothalamus and PFC might also suggest 
abnormal activity of the DRN. The DRN contains about 50% 5HT-ergic cells 
(Azmitta and Segel, 1978; Jacobs and Azmitta, 1992).  The DRN innervates the 
forebrain, NAc and hypothalamus and these are important brain regions regulating 
mood and stress responses (Di Matteo et al., 2001; Molliver, 1989; Deyron et al., 
1998; Mantz et al., 1990). The 5HT-ergic neurons from the DRN innervate the 




2014). Furthermore, the SCN plays an important role in regulating circadian 
rhythms of many biological processes such as melatonin secretion (Klein and 
Moore; Campbell and Dawson, 1990; Redlin et al., 2001). For example, melatonin 
production is regulated by the SCN and under the normal L/D cycle, the light 
period activates the SCN and suppresses melatonin secretion (Klein, 1993; 
Karolczak et al., 2005; Escobar et al., 2011). Melatonin production is also 
regulated by stress exposure (Reiter et al., 2000). Therefore, it is proposed that 
MS and CCL exposure might have impaired SCN activity thereby inhibiting 
melatonin production and increasing the risk of developing depression. This claim 
is in agreement with the claim that melatonin has antidepressant-like actions 
whereas deficiencies in melatonin production are implicated in depressive 
disorders (Beck-Frils et al., 1985; Soutre et al., 1989; Rogers et al., 2003; Crasson 
et al., 2004). Furthermore, agomelatine an analogue of melatonin has 
antidepressant properties and high affinity for 5-HT2C receptors (Cussac et al., 
2002; Millan, 2003). It is believed that the therapeutic effects of agomelatine are 
mediated through 5-HT2C receptors (Cussac et al., 2002; Millan, 2003). These 
findings are also in agreement with the studies demonstrating that inhibition of 5-
HT2C receptors in the NAc elevates DA release leading to an improvement in 
depressive-like behaviours (Campbell and McBride, 1995; Ichikawa and Meltzer, 
1999; Di Matteo et al., 2001; Dremencov et al., 2005).   
Moreover, MT1 and 5-HT2C receptors are expressed in the SCN and in brain 
regions implicated in the pathophysiology of depression (San and Arranz, 2008). 
Most importantly, the 5-HT2C receptor is the only 5-HT receptor that exhibits a CR 
in expression (Holmes et al., 1997). Furthermore, a 5-HT2C receptor agonist has a 
similar effect as a light pulse and inhibits melatonin production. Conversely, a 5-
HT2C receptor antagonist prevents the inhibitory effect of light on melatonin 
synthesis (Kennaway and Emsley, 2006). Thus if chronic stress increases 5-HT2C 
receptor expression and 5-HT2C agonists have an effect that is similar to that of 
light pulses, it is possible that the effects of CCL and MS might have altered 5-
HT2C receptors in the hypothalamus and PFC. Therefore, increased 5-HT2CR 
might also explain the reduced 5-HT levels found in the PFC. However, increased 
5-HT2CR does not explain the increased 5-HT levels in the hypothalamus. 




might be due to a compensatory response by the SCN in order to minimise the 
effects of CCL stress. 
Therefore, CCL might have also increased 5-HT2CR leading to the suppression of 
melatonin secretion implying that CCL is a stressor (Millan et al., 2003; Papp et al., 
2003; Bourin et al., 2004). These results also suggest with suppressed melatonin 
secretion and increased 5-HT2CR results in increased vulnerability to anhedonic 
and depressive like behaviours. Consistent with this suggestion, Moreau et al. 
(1996), showed that stressed rats that had an increased anhedonia index, had 
improved anhedonic like behaviours after chronic antidepressant treatment which 
resulted in desensitized or down-regulated 5-HT2C receptors, further suggesting 
that enhanced 5-HT2CR activity is implicated in depression. It is possible that the 
combination of MS and CCL might have altered 5-HT levels in the hypothalamus 
and PFC by impairing DRN, SCN and 5-HT2CR activity within these regions. 
Future studies are needed to validate the role of these brain regions in mediating 
light-induced 5-HT activity and test whether abnormalities within these regions 
plays a role in depressive behaviours. Several studies have reported anhedonic, 
anxiety and depressive-like behaviours after continuous light exposure suggesting 
that CCL acts as a chronic stressor (Schweizer et al., 2009; Martynhak et al., 
2011; Tapio-Osorio et al., 2013). 
4.3 MOR-1 protein levels in the NAc are resistant to the effects of MS 
and CCL whereas OXR-1 and OXR-2 protein levels in the PFC are 
altered by MS and CCL exposure 
MOR-1 protein levels were not altered by the effects of MS or CCL in the NAc core 
and shell. Moreover, there were no significant differences in MOR-1 protein levels 
when NAc core and shell were averaged to obtain a representation of the function 
of the NAc as a whole.  In contrast to the present findings, rats subjected to MS 
were found to have decreased MOR-1 levels in the NAc which were restored by 
exposure to CCL (Dimatelis et al., 2012). These findings are contradictory since 
both studies were performed using the same MS and CCL paradigm. 




animals, meaning the animals used in this study were more resistant to the effects 
of MS and CCL compared to the animals used in the previous study. Furthermore, 
the fact that SD rats are an outbred strain supports these claims (Wu and Wang, 
2010). 
Similar observations have been reported in other opioid receptors, such as opioid 
receptor-like (ORL1) and KOR whereby there were no significant differences 
reported in opioid receptor-like (ORL1) and KOR between MS rats and control rats 
(Ploj and Nylander, 2003). Instead, MS increased DOR density in the basomedial 
amygdala compared to control rats (Ploj and Nylander, 2003). These results 
provide further evidence of the complexity of the opioid system and suggest that 
the different opioid receptor subtypes have opposing reactions to stressors (Lutz 
and Keiffer, 2013). 
Nevertheless, several studies suggest that MOR is involved in stress responsivity 
(Unterwald et al., 1992; Nikulina et al., 1999). Social defeat stress increased MOR 
mRNA levels in the VTA and chronic cocaine exposure upregulated MOR density 
in the NAc (Unterwald et al., 1992; Nikulina et al., 1999). Furthermore, MOR has 
also been shown to induce anxiolytic and antidepressant properties (Filliol et al., 
2000; Ide et al., 2010; Komatsu et al., 2011). For example, Filliol et al. (2000) 
reported less anxious and reduced depressive-like behaviours in MO knock-out 
mice compared to the wild type mice. It is evident that MOR is implicated in 
depression; however the present findings in the MOR protein levels suggest that 
more research is required to elucidate the function of MOR in the pathophysiology 
of depression. Moreover, future research should also determine the combined 
effects of MS and CCL on DOR and KOR activities in the hope to gain more 
insight into the role of the opioid system in depression. The combined effects of 
MS and CCL are more likely to reveal the function of DOR and KOR in depression 
than when either MS or CCL is used as a sole stressor. 
MS and CCL exposure had an overall effect on OXR-1 protein levels in the PFC. 
Specifically, OXR-1 protein levels of MS rats were significantly increased 
compared to NMS and MS CCL rats. Similar results were found when OXR-1 




OXR-1 protein levels when compared to NMS rats further providing evidence of 
the effect of MS exposure on OXR-1 protein levels. On the other hand, OXR-2 
proteins levels in the PFC were not altered (when only the pixel total (%) was 
analysed) by the effects of MS or CCL. Instead, a trend towards an increase in 
OXR-2 protein levels was observed was observed after MS and CCL exposure.  
When the OXR-2 protein levels were normalised an interaction between MS and 
CCL effect was reported whereby MS rats had increased OXR-2 protein levels 
compared to NMS and MS CCL rats. Furthermore, NMS CCL rats displayed a 
trend towards increase in OXR-2 protein levels when compared to NMS rats. 
These findings suggest that OXR-1 and OXR-2 protein levels are significantly 
influenced by the effects of MS and CCL exposure.  
Similarly, other studies have demonstrated changes in OXR-1 or in both OXR-1 
and OXR-2 receptors following various forms of stress (Karteris et al., 2005; Feng 
et al., 2007; Scott et al., 2011; Arendt et al., 2013). For example, Feng et al. 
(2007) found increased OXR-1 protein levels in the PFC and increased orexin A 
peptide in the hypothalamus of rats subjected to MS. Furthermore, increased 
OXR-1 and orexin A peptide levels were proposed to have caused a reduction in 
total sleep as recorded by an electroencephalogram (EEG) during the light period 
(corresponds to night time in humans). Therefore, the increased OXR-1 protein 
levels might lead to sleep disturbances and circadian abnormalities, phenotypes 
that are well characterised in depression due to an altered orexinergic system 
(Peyron et al., 2000; Salomon et al., 2003; Sakurai et al., 2010; Cao and 
Guilleminauit, 2011).  
Furthermore, increased OXR-1 mRNA expression in the amygdala was positively 
correlated with increased depressive-like behaviours in the FST (Arendt et al., 
2013).  The role of OXR-1 in depression is further supported by the findings that 
OXR-1 KO mice exhibit decreased immobility time in the FST, indicating reduced 
depressive-like behaviours (Scott et al., 2011). Moreover, wild type mice treated 
with an OXR-1 antagonist also display reduced immobility time in the FST, 
indicating antidepressant properties (Scott et al., 2011). Overall, these studies 




support to the increased OXR-1 protein levels after MS, suggesting that OXR-1 is 
associated with depressed moods.  
It has further been postulated that activation of orexin neurons that project to many 
brain areas expressing OXR-1 during stressful events might induce a negative 
affective state that can exacerbate depressive-like behaviours (Scott et al., 2011). 
Moreover, further involvement of OXR-1 in depression comes from a study by 
Rainero et al. (2011) who reported that allelic (specifically the A allele) and 
genotypic frequencies of the polymorphism (rs2271933 G>A) in the OXR-1 gene 
were associated with the increased risk of developing MDD. Collectively, these 
findings highlight the importance of OXR-1 in modulating depressed moods and 
also suggest that drugs acting on OXR-1 might be useful in treating depression. 
Increases in both OXR-1 and OXR-2 protein levels following stress exposure have 
also been by Karteris et al. (2005). In this study, OXR-1 and OXR-2 protein levels 
were significantly increased by a 24 hour food deprivation, another stress 
paradigm (Karteris et al., 2005). Therefore, the increased OXR-1 and OXR-2 
(trend and increased OXR-2 protein levels after normalisation) protein levels in the 
PFC and in the hypothalamus as indicated by Karteris et al. (2005) suggest that 
these receptors are implicated in the regulation of the HPA axis, an important 
system mediating stress responses (Lupien et al., 2009). Both the PFC and the 
hypothalamus control the activity of the HPA axis and disturbances to these brain 
regions (i.e. altered HPA axis activity) has been associated with the risk of 
developing depression (Heim et al., 2000; Lupien et al., 2000; Geoffroy et al., 
2006; Albers et al., 2008; Lupien et al., 2009). Thus the increased OXR-1 and 
OXR-2 protein levels in the PFC as a result of MS and CCL exposure indicate that 
orexin receptors are involved in the stress regulation. It is possible that the altered 
orexin receptors might have impaired the HPA axis activity leading to depression. 
These results are in accordance with the findings reported by various authors that 
have also implicated the orexin receptors in the pathophysiology of depression 
(Karteris et al., 2005; Feng et al., 2007; Scott et al., 2011; Nollet et al., 2011; 




CHAPTER 5: CONCLUSION 
This study demonstrated that MS altered [3H]DA release in the NAc. In addition, 
CCL exacerbated the reduction of [3H]DA release in the NAc. Furthermore, 5-HT 
levels in the hypothalamus and PFC were altered by the effects of MS and CCL. 
These findings add to the existing literature on the long-term effect of MS during 
early brain development and confirm that early life experiences can lead to 
changes in brain development that can influence brain function and affect how the 
brain responds to additional stressors in adulthood (Hout et al., 2001; Vasquez et 
al., 2005; Aisa et al., 2007; Marais et al., 2008; Reus et al., 2011).  
Glutamate-stimulated [3H]DA release in the NAc was significantly decreased in MS 
rats compared to the NMS rats. It was also revealed that addition of CCL in 
adulthood in MS rats aggravated the reduction of [3H]DA release in the NAc shell, 
however no statistical significance was reached. On the other hand, CCL exposure 
significantly altered 5-HT levels in the hypothalamus and PFC both in MS and 
NMS rats. It is important to note that addition of CCL exaggerated the effects of 
MS, whereby MS and CCL combined caused a decrease in 5-HT levels in the 
PFC. Therefore, addition of chronic light exposure during adulthood provides more 
knowledge about the neurobiological mechanisms of MS-induced depression. 
These findings also suggest that the combination of MS and CCL is better than 
when either MS or CCL as used as a sole stressor. 
Despite these significant differences in DA release and 5-HT levels, the precise 
mechanisms leading to the decreased glutamate-stimulated [3H]DA release in the 
NAc and altered 5-HT levels in the hypothalamus and PFC are not fully 
understood. Thus, research is still needed to elucidate the role of DA and 5-HT in 
depression. Further work that deciphers the role of MS in reducing [3H]DA release 
in the NAc might assist in providing more detailed insights into the systems that 
mediate DA release such as the glutamatergic and 5HT-ergic systems. Emphasis  
should be on the interaction between glutamate group II metabotropic receptors (in 
particular mGluR2/3) and the DA system in regulating DA releases Moreover, it is 




whether this influence changes DA release in the NAc. Future work can clarify 
whether an imbalance in 5-HT levels causes a reduction in DA release in the NAc. 
Similarly, future studies should also investigate if additional exposure to CCL in MS 
rats alters 5-HT receptors, particularly in the hypothalamus and PFC in order to 
determine if this has a causal effect on the altered 5-HT levels in the hypothalamus 
and PFC. Future research should also measure DRN activity, since this is the 
brain region where most 5-HT cells are found. Particularly, future research should 
investigate whether projection of these cells from DRN to the hypothalamus and 
PFC causes alterations to the 5-HT levels in the hypothalamus and PFC. It is also 
proposed that investigation of the 5-HT2CR levels in the hypothalamus and PFC 
following MS and CCL exposure might assist in explaining the altered 5-HT levels 
in these brain regions. Especially that 5-HT2CR has been implicated in depression 
(Campbell and McBride, 1995; Ichikawa and Meltzer, 1999; Di Matteo et al., 2001; 
Cussac et al., 2002; Millan, 2003; Dremencov et al., 2005).   
On the other hand, MS and CCL did not alter MOR-1 levels in the NAc. Due to the 
conflicting findings reported on the opioid system, in particular MOR activity in 
depression. Future work should investigate the role of MOR activity in the 
pathophysiology of depression and also determine the combined effects of MS 
and CCL on DOR and KOR activities in the hope to gain more insight into the role 
of the opioid system in depression.   
This study has also added to the limited literature on describing the role of 
orexinergic system in depression. The increased OXR-1 protein levels in 
depression are agreement with several studies that have also documented 
increased OXR-1 protein levels as well as altered orexinergic system in 
depression (Karteris et al., 2005; Feng et al., 2007; Scott et al., 2011; Arendt et al., 
2013). Similarly, the increased trend towards significance in OXR-2 protein levels 
(when the pixel total % was analysed) and the significant increase in OXR-2 
protein levels after the OXR-2 was normalised against p38 provide evidence of the 
role of OXR-2 in depression. Therefore, OXR-1 and OXR-2 protein levels are 
significantly altered by the effects of MS and CCL exposure. Of importance to note 




This study has demonstrated that CCL acts as a stressor, despite not measuring 
HPA activity in response to CCL exposure. Various studies have reported a 
dysregulated HPA axis after light exposure, thus providing support of CCL 
involvement in the HPA axis activity (Blom et al., 1995; Fischeman et al., 1988; 
Mohawk et al., 2007). Thus highlighting the importance of using the CCL paradigm 
in studying depression as well as studying the pathophysiology of bipolar disorder, 
as previously proposed by other authors (Canal-corretger et al., 2001; Flaisher-
Grinberg et al., 2009; Martynhak et al., 2011).  
In conclusion, this study has provided evidence that CCL exaggerates the effects 
















Appendix B: In vitro superfusion  
B1: Krebs buffer reagents 
118 mM Nacl, 
 4.7 mM KCl,  
1.0 mM NaH2PO4  
1.2 mM MgCl2 
1.3 mM Cacl2 
 2.5 mM NaHCO3 
11 mM glucose 
 Add 0.04 mM EDTA 
Make up to 1 litre  
 
B2: Quench standard curve 
 
CPM= Counts per minute 
DPM= Disintegrations per minute 
% Efficiency= (CPM/DPM) * 100 
 
 
Standard CPM DPM  %  Efficiency tSIE 
1 83027 160993 51,6 796 
2 73222 162134 45,2 648 
3 65451 161099 40,6 539 
4 55163 161212 34,2 434 
5 45412 161428 28,1 351 
6 32517 160281 20,3 259 
7 21578 162650 13,3 187 
8 12320 162916 7,6 129 
9 5914 162406 3,6 84 

































Appendix C: ELISA  
C1: RIPA Buffer 
 































Appendix D: Western blot 
















y = 0.0005x - 0.0122 




















Standards (ng/ml) OD1 OD2 OD Ave OD - blank 
2000 1,224 1,224 1,224 0,9885 
1000 0,737 0,72 0,7285 0,493 
500 0,468 0,469 0,4685 0,233 
125 0,275 0,274 0,2745 0,039 




D3: SDS-PAGE recipe for 4 gels (large proteins) 
*Add last, as this will start setting the gel 
D4: SDS-PAGE recipe for 4 gels (small proteins) 
 
*Add last, as this will start setting the gel 
  
REAGENT  12 % SEPARATING GEL  5% STACKING GEL  
dH2O  4.9 ml  4.8  ml  
Acrylamide:bis (30%)   6 ml   1.060 ml 
1.5M Tris buffer pH 8.8  3.8 ml  -  
0.5M Tris buffer pH 6.8  -  2  ml  
10% SDS  150 µl  80  µl  
10% Ammonium persulphate *  150 µl  100 µl  
Temed (add just before 
pouring!)*  
15  µl  20 µl  
Reagent   18 % Separating gel  5 % Stacking gel 
Ethylene glycol 9.6 ml _ 
3M Tris-HCl buffer ,p H 8.45 8 ml 4 ml 
 Acrylamide/bisacrylamide 
(40%) 
19 ml 2 ml 
Deionized water - 10 ml 
40% APS 32 µl 16 µl 




































Appendix E: List of equipments 
Sonicator: MSE Soniprep 150,MSE Scientific Instruments, England 
Centrifudge: Prism Refrigerated Microcentrifuge, Labnet International Inc, USA 
Vortex machine: Vortex-Genie 2, Scientific Industries, USA 
Spectrophotometer, Multiskan FC Thermo Fisher Scientific, Shanghai 
Water bath: Julabo, Paratherm, 5100 electronic waterbath 
Perfusion pump: Watson Marlow 2055, UK 
Beta counter: Packard 1900 CATRI-CARB liquid scintillation analyser 
Gel and transfer apparatus: Bio-rad Power Pac universal, Bio-Rad Laboratories 
Inc. USA 
Orbital shaker: Labnet vortemp 56, Labnet International , Inc.USA 
  
0.2M NaOH 
Weigh 8 g of NaOH pellets into a flask  
Add in 1 L of distilled H20 (stir until the pellets 
are completely dissolved) 







Appendix H: Statistical Data 
Appendix H1: In vitro Superfusion 
Glutamate-stimulated [3H]DA release in the NAc core 
 
 
Glutamate-stimulated [3H]DA release in the NAc core  
Stress Treatment Stress x Treatment Glu-Peak 
1 nMS nL nMSnL 0,30295 
2 nMS nL nMSnL 0,2221 
3 nMS nL nMSnL 0,2083 
4 nMS nL nMSnL 0,28685 
5 nMS nL nMSnL 0,4279 
6 nMS nL nMSnL 0,3164 
7 nMS nL nMSnL 0,04355 
8 nMS nL nMSnL 0,2667 
9 nMS nL nMSnL 0,2136 
10 nMS nL nMSnL 0,2006 
11 nMS nL nMSnL 0,22755 
12 nMS nL nMSnL 0,3031 
13 nMS nL nMSnL 0,393 
14 MS L MSL 0,0664 
15 MS L MSL 0,2095 
16 MS L MSL 0,15295 
17 MS L MSL 0,09865 
18 MS L MSL 0,359 
19 MS L MSL 0,16615 
20 MS L MSL 0,36865 
21 MS L MSL 0,2544 
22 MS L MSL 0,1934 






Glutamate-stimulated [3H]DA release in the NAc core  
Stress Treatment Stress x Treatment Glu-Peak 
24 MS L MSL 0,0781 
25 MS L MSL 0,13515 
26 MS L MSL 0,3948 
27 nMS L nMSL 0,2854 
28 nMS L nMSL 0,1996 
29 nMS L nMSL 0,158055 
30 nMS L nMSL 0,0358 
31 nMS L nMSL 0,0689 
32 nMS L nMSL 0,3842 
33 nMS L nMSL 0,20585 
34 nMS L nMSL 0,2183 
35 nMS L nMSL 0,27135 
36 nMS L nMSL 0,21625 
37 nMS L nMSL 0,19695 
38 MS nL MSnL 0,2247 
39 MS nL MSnL 0,05285 
40 MS nL MSnL 0,2104 
41 MS nL MSnL 0,0969 
42 MS nL MSnL 0,153 
43 MS nL MSnL 0,1701 
44 MS nL MSnL 0,39465 
45 MS nL MSnL 0,0837 
46 MS nL MSnL 0,23795 
47 MS nL MSnL 0,2107 
48 MS nL MSnL 0,12915 
49 MS nL MSnL 0,3411 
50 MS nL MSnL 0,25915 





















Potassium-stimulated [3H]DA release in the NAc core 
Stress Treatment Stress x Treatment K-Peak 
1 nMS nL nMSnL 7,9834 
2 nMS nL nMSnL 6,99275 
3 nMS nL nMSnL 5,271 
4 nMS nL nMSnL 5,1523 
5 nMS nL nMSnL 6,5956 
6 nMS nL nMSnL 1,86525 
7 nMS nL nMSnL 5,72105 
8 nMS nL nMSnL 1,772 
9 nMS nL nMSnL 4,05705 
10 nMS nL nMSnL 2,7783 
11 nMS nL nMSnL 1,1352 
12 MS L MSL 4,8287 
13 MS L MSL 6,8673 
14 MS L MSL 4,3521 
15 MS L MSL 4,9778 
16 MS L MSL 4,40635 
17 MS L MSL 9,27825 
18 MS L MSL 0,4964 
19 MS L MSL 1,64705 
20 MS L MSL 5,84945 
21 MS L MSL 2,0637 
22 MS L MSL 2,4099 
23 MS L MSL 3,16145 







Potassium-stimulated [3H]DA release in the NAc core 
Stress Treatment Stress x Treatment K-Peak 
25 nMS L nMSL 2,30325 
26 nMS L nMSL 5,2367 
27 nMS L nMSL 3,2135 
28 nMS L nMSL 3,69175 
29 nMS L nMSL 3,9349 
30 nMS L nMSL 2,55845 
31 nMS L nMSL 3,42255 
32 nMS L nMSL 4,91475 
33 nMS L nMSL 3,20875 
34 MS nL MSnL 4,192 
35 MS nL MSnL 4,5931 
36 MS nL MSnL 3,92295 
37 MS nL MSnL 3,5067 
38 MS nL MSnL 5,21995 
39 MS nL MSnL 4,5654 
40 MS nL MSnL 1,2619 
41 MS nL MSnL 1,16725 
42 MS nL MSnL 2,846 
43 MS nL MSnL 4,2714 
44 MS nL MSnL 2,8139 


















Glutamate-stimulated [3H]DA release in the NAc shell 
Stress Treatment Stress x Treatment Glu-Peak 
1 nMS nL nMSnL 0,24505 
2 nMS nL nMSnL 0,272 
3 nMS nL nMSnL 0,1322 
4 nMS nL nMSnL 0,29215 
5 nMS nL nMSnL 0,2011 
6 nMS nL nMSnL 0,2475 
7 nMS nL nMSnL 0,168 
8 nMS nL nMSnL 0,08705 
9 nMS nL nMSnL 0,24955 
10 nMS nL nMSnL 0,19785 
11 nMS nL nMSnL 0,2041 
12 MS L MSL 0,1061 
13 MS L MSL 0,06975 
14 MS L MSL 0,21775 
15 MS L MSL 0,28195 
16 MS L MSL 0,2241 
17 MS L MSL 0,1789 
18 MS L MSL 0,09325 
19 MS L MSL 0,141 
20 MS L MSL 0,1021 
21 MS L MSL 0,163 
22 MS L MSL 0,22965 
23 MS L MSL 0,06095 







Glutamate-stimulated [3H]DA release in the NAc shell 
Stress Treatment Stress x Treatment Glu-Peak 
25 MS L MSL 0,09925 
26 nMS L nMSL 0,23375 
27 nMS L nMSL 0,1951 
28 nMS L nMSL 0,192 
29 nMS L nMSL 0,1558 
30 nMS L nMSL 0,0487 
31 nMS L nMSL 0,26705 
32 nMS L nMSL 0,31105 
33 nMS L nMSL 0,25135 
34 nMS L nMSL 0,0791 
35 nMS L nMSL 0,15865 
36 nMS L nMSL 0,11715 
37 MS nL MSnL 0,0729 
38 MS nL MSnL 0,2211 
39 MS nL MSnL 0,21495 
40 MS nL MSnL 0,10695 
41 MS nL MSnL 0,2186 
42 MS nL MSnL 0,194 
43 MS nL MSnL 0,25845 
44 MS nL MSnL 0,1894 
45 MS nL MSnL 0,1459 
46 MS nL MSnL 0,1609 
47 MS nL MSnL 0,26725 


















Potassium-stimulated [3H]DA release in the NAc shell 
 
 
Potassium-stimulated [3H]DA release in the NAc shell 
Stress Treatment Stress x Treatment K SHELL 
1 nMS nL nMSnL 6,9009 
2 nMS nL nMSnL 5,5001 
3 nMS nL nMSnL 4,8092 
4 nMS nL nMSnL 3,5549 
5 nMS nL nMSnL 2,94675 
6 nMS nL nMSnL 2,6446 
7 nMS nL nMSnL 2,45055 
8 nMS nL nMSnL 3,6545 
9 nMS nL nMSnL 2,5945 
10 nMS nL nMSnL 2,5516 
11 MS L MSL 3,7616 
12 MS L MSL 0,62965 
13 MS L MSL 3,9375 
14 MS L MSL 3,9923 
15 MS L MSL 3,8479 
16 MS L MSL 1,01295 
17 MS L MSL 1,817 
18 MS L MSL 1,78395 
19 MS L MSL 1,89945 
20 MS L MSL 1,0693 
21 MS L MSL 2,77445 
22 nMS L nMSL 5,8185 
23 nMS L nMSL 2,1496 
24 nMS L nMSL 2,9691 
25 nMS L nMSL 2,698 





















27 nMS L nMSL 1,2351 
28 nMS L nMSL 0,7807 
29 nMS L nMSL 3,2371 
30 nMS L nMSL 2,2131 
31 MS nL MSnL 3,2881 
32 MS nL MSnL 3,9886 
33 MS nL MSnL 3,115 
34 MS nL MSnL 3,7973 
35 MS nL MSnL 3,9974 
36 MS nL MSnL 0,7394 
37 MS nL MSnL 2,7969 
38 MS nL MSnL 2,30445 
39 MS nL MSnL 1,9373 





















Glutamate-stimulated [3H]DA release in the NAc 
 
 
Glutamate-stimulated [3H]DA release in the NAc 
Stress Treatment Stress x Treatment GluPeak 
1 nMS nL nMSnL 0,274 
2 nMS nL nMSnL 0,24705 
3 nMS nL nMSnL 0,17025 
4 nMS nL nMSnL 0,2895 
5 nMS nL nMSnL 0,3145 
6 nMS nL nMSnL 0,28195 
7 nMS nL nMSnL 0,105775 
8 nMS nL nMSnL 0,176875 
9 nMS nL nMSnL 0,2136 
10 nMS nL nMSnL 0,225075 
11 nMS nL nMSnL 0,2127 
12 nMS nL nMSnL 0,2536 
13 nMS nL nMSnL 0,393 
14 MS L MSL 0,08625 
15 MS L MSL 0,139625 
16 MS L MSL 0,18535 
17 MS L MSL 0,1903 
18 MS L MSL 0,29155 
19 MS L MSL 0,172525 
20 MS L MSL 0,23095 
21 MS L MSL 0,141 
22 MS L MSL 0,17825 
23 MS L MSL 0,1782 
24 MS L MSL 0,1998 
25 MS L MSL 0,069525 






Glutamate-stimulated [3H]DA release in the NAc 
Stress Treatment Stress x Treatment GluPeak 
27 MS L MSL 0,247025 
28 nMS L nMSL 0,2854 
29 nMS L nMSL 0,23375 
30 nMS L nMSL 0,19735 
31 nMS L nMSL 0,175028 
32 nMS L nMSL 0,0958 
33 nMS L nMSL 0,0588 
34 nMS L nMSL 0,325625 
35 nMS L nMSL 0,25845 
36 nMS L nMSL 0,234825 
37 nMS L nMSL 0,175225 
38 nMS L nMSL 0,18745 
39 nMS L nMSL 0,15705 
40 MS nL MSnL 0,1488 
41 MS nL MSnL 0,136975 
42 MS nL MSnL 0,212675 
43 MS nL MSnL 0,101925 
44 MS nL MSnL 0,153 
45 MS nL MSnL 0,19435 
46 MS nL MSnL 0,294325 
47 MS nL MSnL 0,171075 
48 MS nL MSnL 0,213675 
49 MS nL MSnL 0,2107 
50 MS nL MSnL 0,137525 
51 MS nL MSnL 0,251 
52 MS nL MSnL 0,2632 
















Potassium-stimulated [3H]DA release in the NAc 
 
 
Potassium-stimulated [3H]DA release in the NAc 
Stress Treatment Stress x Treatment GluPeak 
1 nMS nL nMSnL 7,44215 
2 nMS nL nMSnL 6,246425 
3 nMS nL nMSnL 5,0401 
4 nMS nL nMSnL 4,3536 
5 nMS nL nMSnL 4,771175 
6 nMS nL nMSnL 2,254925 
7 nMS nL nMSnL 4,0858 
8 nMS nL nMSnL 2,71325 
9 nMS nL nMSnL 3,325775 
10 nMS nL nMSnL 2,66495 
11 nMS nL nMSnL 1,1352 
12 MS L MSL 4,29515 
13 MS L MSL 3,748475 
14 MS L MSL 4,1448 






Potassium-stimulated [3H]DA release in the NAc 
Stress Treatment Stress x Treatment GluPeak 
16 MS L MSL 4,40635 
17 MS L MSL 6,563075 
18 MS L MSL 0,754675 
19 MS L MSL 1,732025 
20 MS L MSL 3,8167 
21 MS L MSL 1,981575 
22 MS L MSL 1,7396 
23 MS L MSL 2,96795 
24 nMS L nMSL 6,637675 
25 nMS L nMSL 2,226425 
26 nMS L nMSL 5,2367 
27 nMS L nMSL 3,0913 
28 nMS L nMSL 3,194875 
29 nMS L nMSL 3,24235 
30 nMS L nMSL 1,896775 
31 nMS L nMSL 2,101625 
32 nMS L nMSL 4,075925 
33 nMS L nMSL 2,710925 
34 MS nL MSnL 3,74005 
35 MS nL MSnL 4,29085 
36 MS nL MSnL 3,92295 
37 MS nL MSnL 3,31085 
38 MS nL MSnL 4,508625 
39 MS nL MSnL 4,2814 
40 MS nL MSnL 1,00065 
41 MS nL MSnL 1,16725 






Potassium-stimulated [3H]DA release in the NAc 
Stress Treatment Stress x Treatment GluPeak 
43 MS nL MSnL 3,287925 
44 MS nL MSnL 2,3756 







Appendix H2: 5-HT concentration in the hypothalamus 
 
 
5HT CONCENTRATION (Hypothalamus) 
Stress Treatment Stress Xtreatment 5-HT concentration 
1 nMS nL nMSnL 1,16951 
2 nMS nL nMSnL 0,564532 
3 nMS nL nMSnL 0,702776 
4 nMS nL nMSnL 1,001948 
5 nMS nL nMSnL 0,947592 
6 nMS nL nMSnL 0,939888 
7 nMS nL nMSnL 1,12457 
8 nMS nL nMSnL 1,09675 
9 nMS nL nMSnL 1,115368 
10 nMS L nMSl 1,01757 
11 nMS L nMSl 0,429284 
12 nMS L nMSl 1,11173 
13 nMS L nMSl 1,06358 
14 nMS L nMSl 1,201824 
15 nMS L nMSl 1,552142 
16 nMS L nMSl 1,318454 
17 nMS L nMSl 1,204392 
18 nMS L nMSl 1,156456 
19 nMS L nMSl 1,145756 
20 MS nL MSnL 0,869482 
21 MS nL MSnL 0,828394 
22 MS nL MSnL 1,102528 
23 MS nL MSnL 0,925122 
24 MS nL MSnL 0,963642 
25 MS nL MSnL 0,925122 
26 MS nL MSnL 1,105952 






5HT CONCENTRATION (Hypothalamus) 
Stress Treatment Stress Xtreatment 5-HT concentration 
28 MS nL MSnL 1,18021 
29 MS nL MSnL 0,906076 
30 MS L MSL 1,023134 
31 MS L MSL 1,20803 
32 MS L MSL 1,529886 
33 MS L MSL 1,198186 
34 MS L MSL 1,280576 
35 MS L MSL 1,212738 
36 MS L MSL 1,284428 
37 MS L MSL 1,383082 
38 MS L MSL 1,24227 





















Appendix H3: 5-HT concentration in the PFC 
 
 
5HT CONCENTRATION (PFC) 
Stress Treatment Stress Xtreatment 5-HT concentration 
1 nMS nL nMSnL 0,471656 
2 nMS nL nMSnL 0,907788 
3 nMS nL nMSnL 0,792442 
4 nMS nL nMSnL 0,456034 
5 nMS nL nMSnL 0,610328 
6 nMS nL nMSnL 0,958506 
7 nMS nL nMSnL 0,462454 
8 nMS nL nMSnL 0,373216 
9 nMS nL nMSnL 0,4708 
10 nMS nL nMSnL 0,417728 
11 nMS L nMSL 0,402106 
12 nMS L nMSL 0,359734 
13 nMS L nMSL 0,308802 
14 nMS L nMSL 0,442552 
15 nMS L nMSL 0,267928 
16 nMS L nMSL 0,124762 
17 nMS L nMSL 0,047722 
18 nMS L nMSL 0,200732 
19 nMS L nMSL 0,206296 
20 MS nL MSnL 0,3103 
21 MS nL MSnL 0,49862 
22 MS nL MSnL 0,40125 
23 MS nL MSnL 0,406386 
24 MS nL MSnL 0,695928 
25 MS nL MSnL 0,376426 
26 MS nL MSnL 0,472512 






5HT CONCENTRATION (PFC) 
Stress Treatment Stress Xtreatment 5-HT concentration 
28 MS nL MSnL 0,29639 
29 MS nL MSnL 0,386698 
30 MS L MSL 0,268784 
31 MS L MSL 0,217424 
32 MS L MSL 0,27927 
33 MS L MSL 0,33919 
34 MS L MSL 0,578014 
35 MS L MSL 0,054998 
36 MS L MSL 0,122408 
37 MS L MSL 0,19581 
38 MS L MSL 0,18083 





























Appendix H4: MOR-1 protein levels in the NAc core 
 MOR-1 protein levels in the NAc core 
Stress Treatment Stress x Treatment Pixel Total % 
1 nMS nL nMSnL 13,57 
2 nMS nL nMSnL 11,46 
3 nMS nL nMSnL 14,9082696 
4 nMS nL nMSnL 10,6659039 
5 nMS nL nMSnL 13,3 
6 nMS nL nMSnL 17,29 
7 nMS nL nMSnL 8,03545877 
8 nMS nL nMSnL 5,90612322 
9 nMS nL nMSnL 13,207752 
10 nMS nL nMSnL 16,8629916 
11 nMS L nMSL 11,96 
12 nMS L nMSL 10,56 
13 nMS L nMSL 11,23026 
14 nMS L nMSL 15,975963 
15 nMS L nMSL 8,08 
16 nMS L nMSL 15,5 
17 nMS L nMSL 17,9353626 
18 nMS L nMSL 10,4946121 
19 nMS L nMSL 16,7916431 
20 MS nL MSnL 9,1 
21 MS nL MSnL 16,32 
22 MS nL MSnL 14,8852016 
23 MS nL MSnL 11,42 
24 MS nL MSnL 11,99 
25 MS nL MSnL 16,8830843 















27 MS nL MSnL 7,60807589 
28 MS nL MSnL 18,6270906 
29 MS L MSL 11,89 
30 MS L MSL 15,14 
31 MS L MSL 11,9350812 
32 MS L MSL 7,89932075 
33 MS L MSL 6,53 
34 MS L MSL 15,89 
35 MS L MSL 8,63271355 
36 MS L MSL 12,8593152 













MOR-1 protein levels in the NAc core (normalised against α-tubulin) 
 
 
MOR-1 protein levels in the NAc core normalised 
Stress Treatment Stress x Treatment Pixel Total % 
1 nMS nL nMSnL 122,112805 
2 nMS nL nMSnL 106,474375 
3 nMS nL nMSnL 113,284723 
4 nMS nL nMSnL 95,6583313 
5 nMS nL nMSnL 80,1204819 
6 nMS nL nMSnL 137,331215 
7 nMS nL nMSnL 76,6011322 
8 nMS nL nMSnL 51,3129733 
9 nMS nL nMSnL 97,9803559 
10 nMS nL nMSnL 108,391152 
11 nMS L nMSL 85,9613236 
12 nMS L nMSL 91,8453559 
13 nMS L nMSL 102,186169 
14 nMS L nMSL 123,940753 
15 nMS L nMSL 63,6721828 
16 nMS L nMSL 142,332415 
17 nMS L nMSL 125,422116 
18 nMS L nMSL 93,0373411 
19 nMS L nMSL 119,683843 
20 MS nL MSnL 68,2108123 
21 MS nL MSnL 123,892095 
22 MS nL MSnL 118,986423 
23 MS nL MSnL 82,8136331 
24 MS nL MSnL 108,31075 
25 MS nL MSnL 121,987603 
26 MS nL MSnL 107,519289 












28 MS nL MSnL 131,919905 
29 MS L MSL 93,5510508 
30 MS L MSL 112,231573 
31 MS L MSL 111,024011 
32 MS L MSL 52,3133825 
33 MS L MSL 53,3061224 
34 MS L MSL 157,01581 
35 MS L MSL 79,3447937 
36 MS L MSL 105,5773 













Alpha tubulin protein levels in the NAc core 
 
 
Alpha tubulin protein levels in the  NAc core 
Stress Treatment Stress x treatment Pixel Total % 
1 nMS nL nMSnL 11,1126757 
2 nMS nL nMSnL 10,7631531 
3 nMS nL nMSnL 13,16 
4 nMS nL nMSnL 11,15 
5 nMS nL nMSnL 16,6 
6 nMS nL nMSnL 12,59 
7 nMS nL nMSnL 10,49 
8 nMS nL nMSnL 11,51 
9 nMS nL nMSnL 13,48 
10 nMS nL nMSnL 15,5575352 
11 nMS L nMSL 13,9132339 
12 nMS L nMSL 11,4975873 
13 nMS L nMSL 10,99 
14 nMS L nMSL 12,89 
15 nMS L nMSL 12,69 
16 nMS L nMSL 10,89 
17 nMS L nMSL 14,3 
18 nMS L nMSL 11,28 
19 nMS L nMSL 14,03 
20 MS nL MSnL 13,3409935 
21 MS nL MSnL 13,1727533 
22 MS nL MSnL 12,51 
23 MS nL MSnL 13,79 
24 MS nL MSnL 11,07 
25 MS nL MSnL 13,84 













27 MS nL MSnL 12,73 
28 MS nL MSnL 14,12 
29 MS L MSL 12,7096381 
30 MS L MSL 13,4899651 
31 MS L MSL 10,75 
32 MS L MSL 15,1 
33 MS L MSL 12,25 
34 MS L MSL 10,12 
35 MS L MSL 10,88 
36 MS L MSL 12,18 










Appendix H5: MOR-1 protein levels in the NAc shell  
 
 
MOR-1 protein levels in the NAc shell  
Stress Treatment Stress x Treatment Pixel Total % 
1 nMS nL nMSnL 11,3544746 
2 nMS nL nMSnL 15,8963433 
3 nMS nL nMSnL 5,6898358 
4 nMS nL nMSnL 15,6187939 
5 nMS nL nMSnL 8,91313277 
6 nMS nL nMSnL 9,14427415 
7 nMS nL nMSnL 23,5568667 
8 nMS nL nMSnL 11,65 
9 nMS nL nMSnL 7,85 
10 nMS L nMSL 12,0263667 
11 nMS L nMSL 6,89726002 
12 nMS L nMSL 19,1819735 
13 nMS L nMSL 11,2211645 
14 nMS L nMSL 15,7618579 
15 nMS L nMSL 16,75 
16 nMS L nMSL 12,76 
17 MS nL MSnL 16,2197326 
18 MS nL MSnL 12,7633192 
19 MS nL MSnL 15,1849501 
20 MS nL MSnL 18,601239 
21 MS nL MSnL 11,6267616 
22 MS nL MSnL 13,2098364 
23 MS nL MSnL 12,1929618 
24 MS nL MSnL 15,757251 
25 MS nL MSnL 8,42 














27 MS L MSL 10,136107 
28 MS L MSL 11,0473023 
29 MS L MSL 7,36592122 
30 MS L MSL 10,5396751 
31 MS L MSL 11,8299423 
32 MS L MSL 6,02820446 
33 MS L MSL 21,18 





















MOR1 protein levels in the NAc shell normalised against α tubulin 
 
 
MOR1 protein levels in the shell (normalised) 
Stress Treatment Stress x 
Treatment 
Pixel Total % 
1 nMS nL nMSnL 90,9085233 
2 nMS nL nMSnL 101,698554 
3 nMS nL nMSnL 56,4810344 
4 nMS nL nMSnL 118,729773 
5 nMS nL nMSnL 77,7404482 
6 nMS nL nMSnL 83,4430215 
7 nMS nL nMSnL 171,623058 
8 nMS nL nMSnL 81,0716771 
9 nMS nL nMSnL 68,6789151 
10 nMS L nMSL 100,219722 
11 nMS L nMSL 69,8933789 
12 nMS L nMSL 120,315749 
13 nMS L nMSL 96,0711158 
14 nMS L nMSL 106,259747 
15 nMS L nMSL 158,31758 
16 nMS L nMSL 106,688963 
17 MS nL MSnL 115,525161 
18 MS nL MSnL 104,360746 
19 MS nL MSnL 118,438567 
20 MS nL MSnL 128,792734 
21 MS nL MSnL 83,0910791 
22 MS nL MSnL 116,042596 
23 MS nL MSnL 91,0371232 
24 MS nL MSnL 142,247266 
25 MS nL MSnL 70,519263 
26 MS nL MSnL 71,3517665 
27 MS L MSL 97,1822338 
28 MS L MSL 94,5125684 











30 MS L MSL 88,2875051 
31 MS L MSL 110,228347 
32 MS L MSL 60,2676243 
33 MS L MSL 148,735955 




Alpha tubulin protein levels in the NAc shell 
 
 
Alpha tubulin protein levels in the NAc shell 
Stress Treatment Stress x Treatment Total Pixel 
(%) 
1 nMS nL nMSnL 12,49 
2 nMS nL nMSnL 15,6308449 
3 nMS nL nMSnL 10,0738874 
4 nMS nL nMSnL 13,1549092 
5 nMS nL nMSnL 11,4652449 
6 nMS nL nMSnL 10,9587045 
7 nMS nL nMSnL 13,7259334 
8 nMS nL nMSnL 14,37 
9 nMS nL nMSnL 11,43 
10 nMS L nMSL 12 
11 nMS L nMSL 9,86825952 
12 nMS L nMSL 15,943028 
13 nMS L nMSL 11,6800606 
14 nMS L nMSL 14,833329 
15 nMS L nMSL 10,58 
16 nMS L nMSL 11,96 
17 MS nL MSnL 14,04 
18 MS nL MSnL 12,23 
19 MS nL MSnL 12,8209506 
20 MS nL MSnL 14,4427706 
21 MS nL MSnL 13,9927917 
22 MS nL MSnL 11,3836098 
23 MS nL MSnL 13,3933954 
24 MS nL MSnL 11,0773665 












26 MS nL MSnL 13,02 
27 MS L MSL 10,43 
28 MS L MSL 11,6887124 
29 MS L MSL 10,3514859 
30 MS L MSL 11,9379011 
31 MS L MSL 10,7322142 
32 MS L MSL 10,0023927 
33 MS L MSL 14,24 












MOR-1 protein levels in the NAc 
 
 
MOR-1 protein levels in the nucleus accumbens  
STRESS TREATMENT STRESS X TREATMENT Pixel  density (%) 
1 nMS nL nMSnL 18,5634333 
2 nMS nL nMSnL 11,7431833 
3 nMS nL nMSnL 15,4023064 
4 nMS nL nMSnL 11,157952 
5 nMS nL nMSnL 13,0867321 
6 nMS nL nMSnL 6,86264729 
7 nMS nL nMSnL 17,29 
8 nMS nL nMSnL 16,8629916 
9 nMS nL nMSnL 11,3544746 
10 nMS nL nMSnL 15,6187939 
11 nMS nL nMSnL 8,91313277 
12 nMS nL nMSnL 9,14427415 
13 nMS nL nMSnL 7,85 
14 nMS L nMSL 9,06375999 
15 nMS L nMSL 10,42 
16 nMS L nMSL 13,3605823 
17 nMS L nMSL 17,3426813 
18 nMS L nMSL 11,96 
19 nMS L nMSL 10,56 
20 nMS L nMSL 15,975963 
21 nMS L nMSL 10,4946121 
22 nMS L nMSL 16,7916431 
23 nMS L nMSL 19,1819735 
24 nMS L nMSL 15,7618579 
25 MS nL MSnL 9,61805349 
26 MS nL MSnL 12,37 






28 MS nL MSnL 14,254923 
29 MS nL MSnL 13,5421917 
30 MS nL MSnL 13,1922991 
31 MS nL MSnL 14,8852016 
32 MS nL MSnL 11,42 
33 MS nL MSnL 12,7633192 
34 MS nL MSnL 9,29 
35 MS L MSL 6,94796061 
36 MS L MSL 13,4686512 
37 MS L MSL 7,33045901 
38 MS L MSL 11,89 
39 MS L MSL 15,14 
40 MS L MSL 11,9350812 
41 MS L MSL 7,89932075 
42 MS L MSL 3,95745024 
43 MS L MSL 10,5396751 
44 MS L MSL 21,18 













Appendix H6: OXR-1 protein levels in the PFC  
 
 
OXR-1 protein levels in the PFC 
Stress Treatment Stress x Treatment Pixel Total (%) 
1 NMS nL nMSnL 18,12 
2 nMS nL nMSnL 8,32 
3 nMS nL nMSnL 3,65 
4 nMS nL nMSnL 11,36 
5 nMS nL nMSnL 4,07 
6 nMS nL nMSnL 8,42 
7 nMS nL nMSnL 8,56 
8 nMS nL nMSnL 8,07 
9 nMS nL nMSnL 8,94111798 
10 nMS nL nMSnL 25,9645639 
11 nMS nL nMSnL 8,99554586 
12 nMS L nMSL 16,14 
13 nMS L nMSL 6,63 
14 nMS L nMSL 11,18 
15 nMS L nMSL 21,99 
16 nMS L nMSL 12,53 
17 nMS L nMSL 17,63 
18 nMS L nMSL 16,46 
19 nMS L nMSL 11,68 
20 nMS L nMSL 13,4175287 
21 MS nL MSnL 11,22 
22 MS nL MSnL 19,13 
23 MS nL MSnL 11,8 
24 MS nL MSnL 17,26 
25 MS nL MSnL 19,63 
26 MS nL MSnL 16,8 






OXR-1 protein levels in the PFC 
Stress Treatment Stress x Treatment Pixel Total (%) 
28 MS nL MSnL 13,03 
29 MS nL MSnL 11,7275855 
30 MS L MSL 11 
31 MS L MSL 9,45 
32 MS L MSL 10,87 
33 MS L MSL 11,9 
34 MS L MSL 11,65 
35 MS L MSL 9,26 
36 MS L MSL 16,29 
37 MS L MSL 6,28 





















OXR1 protein levels normalised against p38 
 
 
OXR1 protein levels normalised against  p38 
Stress Treatment Stress x Treatment Pixel total (%) 
1 NMS nL nMSnL 96,5370272 
2 nMS nL nMSnL 70,2702703 
3 nMS nL nMSnL 21,6745843 
4 nMS nL nMSnL 104,220183 
5 nMS nL nMSnL 23,7456243 
6 nMS nL nMSnL 73,8596491 
7 nMS nL nMSnL 83,3495618 
8 nMS nL nMSnL 62,1247113 
9 nMS nL nMSnL 56,0869108 
10 nMS nL nMSnL 232,408046 
11 nMS nL nMSnL 83,4032134 
12 nMS L nMSL 125,407925 
13 nMS L nMSL 72,6177437 
14 nMS L nMSL 80,3738318 
15 nMS L nMSL 217,29249 
16 nMS L nMSL 97,8142077 
17 nMS L nMSL 164,1527 
18 nMS L nMSL 151,425943 
19 nMS L nMSL 92,0409771 
20 nMS L nMSL 92,4214056 
21 MS nL MSnL 85,1289833 
22 MS nL MSnL 171,569507 
23 MS nL MSnL 100,084818 
24 MS nL MSnL 139,193548 
25 MS nL MSnL 156,539075 
26 MS nL MSnL 146,853147 




28 MS nL MSnL 88,1000676 
29 MS nL MSnL 104,725976 
30 MS L MSL 107,212476 
31 MS L MSL 73,8858483 
32 MS L MSL 96,1946903 
33 MS L MSL 93,4799686 
34 MS L MSL 100,344531 
35 MS L MSL 75,1623377 
36 MS L MSL 133,634126 
37 MS L MSL 44,7931526 









P38 protein levels in the PFC  
 
 
P38 protein levels in the PFC  
Stress Treatment Stress x Treatment Pixel Total (%) 
1 nMS nL nMSnL 18,77 
2 nMS nL nMSnL 11,84 
3 nMS nL nMSnL 16,84 
4 nMS nL nMSnL 10,9 
5 nMS nL nMSnL 17,14 
6 nMS nL nMSnL 11,4 
7 nMS nL nMSnL 10,27 
8 nMS nL nMSnL 12,99 
9 nMS nL nMSnL 15,9415412 
10 nMS nL nMSnL 11,1719729 
11 nMS nL nMSnL 10,7856106 
12 nMS L nMSL 12,87 
13 nMS L nMSL 9,13 
14 nMS L nMSL 13,91 
15 nMS L nMSL 10,12 
16 nMS L nMSL 12,81 
17 nMS L nMSL 10,74 
18 nMS L nMSL 10,87 
19 nMS L nMSL 12,69 
20 nMS L nMSL 14,5177717 
21 MS nL MSnL 13,18 
22 MS nL MSnL 11,15 
23 MS nL MSnL 11,79 
24 MS nL MSnL 12,4 
25 MS nL MSnL 12,54 






P38 protein levels in the PFC  
Stress Treatment Stress x Treatment Pixel Total (%) 
27 MS nL MSnL 12,17 
28 MS nL MSnL 14,79 
29 MS nL MSnL 11,198354 
30 MS L MSL 10,26 
31 MS L MSL 12,79 
32 MS L MSL 11,3 
33 MS L MSL 12,73 
34 MS L MSL 11,61 
35 MS L MSL 12,32 
36 MS L MSL 12,19 
37 MS L MSL 14,02 













Appendix H7: OXR-2 protein levels in the PFC  
 
 
OXR-2 protein levels in the PFC 
Stress Treatment Stress x Treatment Pixel Total (%) 
1 nMS nL nMSnL 20,72 
2 nMS nL nMSnL 9,93 
3 nMS nL nMSnL 12,86 
4 nMS nL nMSnL 9,97 
5 nMS nL nMSnL 7,47 
6 nMS nL nMSnL 11,54 
7 nMS nL nMSnL 11,6 
8 nMS nL nMSnL 8,52 
9 nMS nL nMSnL 12,8385741 
10 nMS nL nMSnL 11,9178652 
11 nMS nL nMSnL 9,85887009 
12 nMS L nMSL 10,54 
13 nMS L nMSL 10,99 
14 nMS L nMSL 11,53 
15 nMS L nMSL 15 
16 nMS L nMSL 14,2 
17 nMS L nMSL 14,9 
18 nMS L nMSL 12,53 
19 nMS L nMSL 12,79 
20 nMS L nMSL 11,4413762 
21 MS nL MSnL 10,61 
22 MS nL MSnL 15,32 
23 MS nL MSnL 11,57 
24 MS nL MSnL 15,42 
25 MS nL MSnL 15,14 
26 MS nL MSnL 14,58 






OXR-2 protein levels in the PFC 
Stress Treatment Stress x Treatment Pixel Total (%) 
28 MS nL MSnL 14,9 
29 MS nL MSnL 18,9662368 
30 MS nL MSnL 10,0481724 
31 MS L MSL 9,2 
32 MS L MSL 12,69 
33 MS L MSL 10,38 
34 MS L MSL 13,27 
35 MS L MSL 9,1 
36 MS L MSL 13,06 
37 MS L MSL 11,78 
38 MS L MSL 14,52 


















OXR-2 protein levels in the PFC normalised against p38 
Stress Treatment Stress x Treatment Pixel Total (%) 
1 nMS nL nMSnL 144,289694 
2 nMS nL nMSnL 85,0171233 
3 nMS nL nMSnL 98,393267 
4 nMS nL nMSnL 83,6409396 
5 nMS nL nMSnL 57,5944487 
6 nMS nL nMSnL 96,1666667 
7 nMS nL nMSnL 77,1789754 
8 nMS nL nMSnL 73,5751295 
9 nMS nL nMSnL 88,440776 
10 nMS nL nMSnL 98,1561652 
11 nMS nL nMSnL 81,1885423 
12 nMS L nMSL 105,717151 
13 nMS L nMSL 87,0839937 
14 nMS L nMSL 97,2175379 
15 nMS L nMSL 119,142176 
16 nMS L nMSL 113,964687 
17 nMS L nMSL 121,632653 
18 nMS L nMSL 100,64257 
19 nMS L nMSL 104,153094 
20 nMS L nMSL 97,9182954 
21 MS nL MSnL 92,4216028 
22 MS nL MSnL 111,743253 
23 MS nL MSnL 92,2647528 
24 MS nL MSnL 125,264013 
25 MS nL MSnL 106,770099 
26 MS nL MSnL 118,729642 
27 MS nL MSnL 104,870385 




29 MS nL MSnL 140,849938 
30 MS nL MSnL 96,7631064 
31 MS L MSL 76,2220381 
32 MS L MSL 89,9362155 
33 MS L MSL 91,4537445 
34 MS L MSL 92,4094708 
35 MS L MSL 76,3422819 
36 MS L MSL 109,380235 
37 MS L MSL 108,371665 
38 MS L MSL 113,26053 














P38 Protein levels in the PFC (OXR-2) 
 
 
P38 Protein levels in the PFC (OXR-2) 
Stress Treatment Stress x Treatment Var4 
1 nMS nL nMSnL 14,36 
2 nMS nL nMSnL 11,68 
3 nMS nL nMSnL 13,07 
4 nMS nL nMSnL 11,92 
5 nMS nL nMSnL 12,97 
6 nMS nL nMSnL 12 
7 nMS nL nMSnL 15,03 
8 nMS nL nMSnL 11,58 
9 nMS nL nMSnL 14,5165779 
10 nMS nL nMSnL 12,1417388 
11 nMS nL nMSnL 12,1431791 
12 nMS L nMSL 9,97 
13 nMS L nMSL 12,62 
14 nMS L nMSL 11,86 
15 nMS L nMSL 12,59 
16 nMS L nMSL 12,46 
17 nMS L nMSL 12,25 
18 nMS L nMSL 12,45 
19 nMS L nMSL 12,28 
20 nMS L nMSL 11,6846154 
21 MS nL MSnL 11,48 
22 MS nL MSnL 13,71 
23 MS nL MSnL 12,54 
24 MS nL MSnL 12,31 
25 MS nL MSnL 14,18 






P38 Protein levels in the PFC (OXR-2) 
Stress Treatment Stress x Treatment Var4 
27 MS nL MSnL 12,73 
28 MS nL MSnL 12,23 
29 MS nL MSnL 13,4655628 
30 MS nL MSnL 10,3843011 
31 MS L MSL 12,07 
32 MS L MSL 14,11 
33 MS L MSL 11,35 
34 MS L MSL 14,36 
35 MS L MSL 11,92 
36 MS L MSL 11,94 
37 MS L MSL 10,87 
38 MS L MSL 12,82 
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